0001554795-18-000257.txt : 20180820 0001554795-18-000257.hdr.sgml : 20180820 20180820144033 ACCESSION NUMBER: 0001554795-18-000257 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180820 DATE AS OF CHANGE: 20180820 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OZOP SURGICAL CORP. CENTRAL INDEX KEY: 0001679817 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISCELLANEOUS AMUSEMENT & RECREATION [7990] IRS NUMBER: 352540672 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55976 FILM NUMBER: 181028013 BUSINESS ADDRESS: STREET 1: 319 CLEMATIS STREET STREET 2: SUITE 714 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 760-466-8076 MAIL ADDRESS: STREET 1: 319 CLEMATIS STREET STREET 2: SUITE 714 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: Newmarkt Corp. DATE OF NAME CHANGE: 20160715 10-Q 1 ozsc0818form10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended: June 30, 2018

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from ___________ to____________

Commission File Number: 000-55976

OZOP SURGICAL CORP.

(Exact name of registrant as specified in its charter)

Nevada		35-2540672
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

319 Clematis Street, Suite 714, West Palm Beach FL 33401

(Address of principal executive offices) (zip code)

(760) 466-8076

(Registrant’s telephone number, including area code)

Not applicable.

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☑ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer (Do not check if a smaller reporting company)	☐	Smaller reporting company	☑
		Emerging growth company	☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No

As of August 14, 2018, there were 26,297,500 shares outstanding of the registrant’s common stock.

Ozop Surgical Corp.

INDEX

PART I. FINANCIAL INFORMATION

	ITEM 1	Financial Statements (Unaudited)
		Condensed Consolidated Balance Sheets as of June 30, 2018 (Unaudited) and December 31, 2017	3
		Condensed Consolidated Statement of Comprehensive Loss for the three and six months ended June 30, 2018 and 2017 (Unaudited)	4
		Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2018 and 2017 (Unaudited)	5
		Notes to Interim Unaudited Consolidated Financial Statements	6
	ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
	ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	21
	ITEM 4.	Controls and Procedures	21

PART II. OTHER INFORMATION

	ITEM 1.	Legal Proceedings	22
	ITEM 1A.	Risk Factors	22
	ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22
	ITEM 3.	Defaults Upon Senior Securities	22
	ITEM 4.	Mine Safety Disclosures	22
	ITEM 5.	Other Information	22
	ITEM 6.	Exhibits	23

	SIGNATURES		24

Ozop Surgical, Corp
Condensed Consolidated Balance Sheet
(Unaudited)

		June 30,			December 31,
		2018			2017
ASSETS
Current Assets
Cash	$	275,412		$	110,792
Prepaid expenses		55,082			18,171
Accounts receivable		52,206			—
Inventory		245,535			—
Total Current Assets		628,235			128,963

Office equipment, net		5,829			1,323
Patents and trademarks, net		137,283			141,695
License Rights		489,151			—
TOTAL ASSETS	$	1,260,498		$	271,981

LIABILITIES AND STOCKHOLDERS' DEFICIT
Liabilities
Current Liabilities
Accounts payable and accrued expenses	$	451,477		$	141,931
Accounts payable and accrued expenses, related parties		404,379			220,012
Convertible notes payable, net of discounts		213,018			735,500
Notes Payable		662,805			430,000
License fee payable		250,000			—
Derivative liabilities		659,895			—
Total Current Liabilities		2,641,574			1,527,443

Stockholders' Deficit
Preferred stock (10,000,000 shares authorized, par value $0.001, no shares issued and outstanding)		—			—
Common stock (290,000,000 shares authorized par value $0.001 26,297,500 and 13,000,000 shares issued and outstanding June 30, 2018 and December 31, 2017, respectively)		26,298			13,000
Common stock to be issued (1,180,768 shares issuable June 30, 2018)		1,181			—
Additional paid in capital		1,024,633			291,155
Accumulated Deficit		(2,429,023	)		(1,562,476	)
Stock subscription receivable		(7,600	)		—
Accumulated comprehensive income		3,435			2,859
Total Stockholders' Deficit		(1,381,076	)		(1,255,462	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	1,260,498		$	271,981

See notes to condensed consolidated financial statements.

Ozop Surgical, Corp
Condensed Consolidated Statement of Comprehensive Loss
(Unaudited)

	For the Three Months Ended						For the Six Months Ended
	June 30, 2018			June 30, 2017			June 30, 2018			June 30, 2017
Revenue	$	105,764		$	43,893		$	117,690		$	56,771
Cost of Goods		63,628			29,145			68,828			38,870
Gross Profit		42,136			14,748			48,862			17,901

Operating expenses:
Research and development		—			41,856			10,565			84,237
General and administrative		271,312			186,894			498,229			467,995
Total operating expenses		271,312			228,750			508,794			552,232

Operating loss		(229,176	)		(214,002	)		(459,932	)		(534,331	)

Other (income) expenses:
Interest expense		933,817			8,869			962,364			13,719
Gain on change in fair value of derivatives		(255,469	)		—			(255,469	)		—
Gain on extinguishment of debt		(300,280	)		—			(300,280	)		—
Total Other Expenses (Income)		378,068			8,869			406,615			13,719

Net Loss	$	(607,244	)	$	(222,871	)	$	(866,547	)	$	(548,050	)

Other comprehensive income (loss):
Foreign currency translation adjustment		(328	)		20,045			576			97
Comprehensive loss	$	(607,572	)	$	(202,826	)	$	(865,971	)	$	(547,953	)

Loss per share	$	(0.02	)	$	(0.02	)	$	(0.04	)		(0.05	)

Weighted average shares outstanding
Basic and diluted		25,918,389			13,000,000			22,692,528			10,400,000

See notes to condensed consolidated financial statements.

OZOP SURGICAL, CORP
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited)

	For the six months ended
	June 30, 2018			June 30, 2017
Cash flows from operating activities:
Net loss	$	(866,547	)	$	(548,050	)
Adjustments to reconcile net loss to net cash used in operations
Non-cash interest expense		895,962			—
Amortization and depreciation		4,847			297
Gain on fair value change of derivatives		(255,469	)		—
Gain on extinguishment of debt		(300,280	)		—
Issuance of convertible notes for fees		9,500			1,875
Changes in operating assets and liabilities:
Inventory		16,334			—
Accounts receivable		(41,511	)		—
Prepaid expenses		(6,911	)		(56	)
Accounts payable and accrued expenses		49,612			(4,414	)
Accounts payable and accrued expenses, related parties		183,717			248,288
Net cash used in operating activities		(310,746	)		(302,060	)

Cash flows from investing activities:
Cash acquired in acquisitions		21,580			—
Purchase of office and computer equipment		(4,941	)		(1,944	)
Net cash provided by (used in) investing activities		16,639			(1,944	)

Cash flows from financing activities:
Redemption of common shares		(350,000	)		—
Proceeds from issuances of convertible notes payable		400,000			50,000
Proceeds from issuances of notes payable		200,000			200,000
Proceeds from sale of common stock		250,000			—
Payments of principal of convertible note payable and notes payable		(41,846	)		—
Net cash provided by financing activities		458,154			250,000

Effects of exchange rate on cash and cash equivalents	$	573		$	96

Net increase (decrease) in cash and cash equivalents		164,620			(53,908	)

Cash and cash equivalents, Beginning of period		110,792			117,348

Cash and cash equivalents, End of period	$	275,412		$	63,440

Supplemental disclosure of cash flow information:
Cash paid for interest	$	56,323		$	7,619
Cash paid for income taxes	$	—		$	—

Schedule of non-cash Investing or Financing Activity:
Original issue discount included in notes payable	$	122,175		$	—
Issuance of common stock upon convertible note and accrued interest conversion	$	589,176		$	—
Issuance of common stock for contribution of intellectual property	$	—		$	150,000

Acquisition of Spinus, LLC
Issuance of Common stock as consideration	$	250,000
Assumed liabilities		532,289
Accounts receivable		(19,054	)
Inventory		(253,510	)
Other Assets		(250,000	)
Intangible assets		(239,151	)
Cash acquired	$	20,574

Acquisition of Newmarkt
Issuance of Common stock as consideration	$	2,798
Assumed liabilities		62,464
Paid in capital		(53,990	)
Inventory		(8,359	)
Prepaid expenses		(1,907	)
Intangible assets		—
Cash acquired	$	1,006

See notes to condensed consolidated financial statements.

OZOP SURGICAL, CORP

Notes to Condensed Consolidated Financial Statements

June 30, 2018

(Unaudited)

NOTE 1 - ORGANIZATION

Business

Ozop Surgical Corp. (“the Company”, “we”, “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada, for the purpose of the renting different kind of Segway and bicycles, dual wheels self-balancing electric scooter and related safety equipment. Following the acquisition of OZOP Surgical, Inc. as discussed below, we have been engaged in the business of inventing, designing, developing, manufacturing and globally distributing innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties.

Reverse Merger

On April 13, 2018, we entered into and completed a share exchange agreement (the "Share Exchange Agreement") with OZOP Surgical, Inc. (“OZOP”), the shareholders of OZOP (the “OZOP Shareholders”) and Denis Razvodovskij, the holder of 2,000,000 shares of our common stock. Pursuant to the terms of the Share Exchange Agreement, the OZOP Shareholders transferred and exchanged 100% of the capital stock of OZOP in exchange for an aggregate of 25,000,000 newly issued shares of our common stock (the “Share Exchange”). After giving effect to the redemption of 2,000,000 shares of our common stock pursuant to the Redemption Agreement discussed below and the issuance of 25,000,000 shares of our common stock pursuant to the Share Exchange Agreement, we had 25,797,500 shares of common stock issued and outstanding, with the OZOP Shareholders, as a group, owning 96.9% of such shares. Our executive officers and directors, as a group, own 19,900,000 of our shares representing 77.1% of our issued and outstanding shares of common stock. The merger was accounted for as a reverse merger, whereby OZOP was considered the accounting acquirer and became a wholly-owned subsidiary of the Company. In accordance with the accounting treatment for a “reverse merger” or a “reverse acquisition,” the Company’s historical financial statements prior to the reverse merger will be replaced with the historical financial statements of OZOP prior to the reverse merger, in all future filings with the U.S. Securities and Exchange Commission (the “SEC”).

In connection with the acquisition of OZOP, we purchased and redeemed 2,000,000 shares of our common stock from Mr. Razvodovskij for a total purchase price of $350,000 pursuant to a Share Redemption Agreement (the “Redemption Agreement”). Pursuant to the terms of the Share Exchange Agreement, effective April 13, 2018, Mr. Razvodovskij resigned as the Company's Chief Executive Officer, Chief Financial Officer, Secretary, and sole director, and Michael Chermak, Salman J. Chaudhry and Eric Siu were named as directors of the Company.

On May 8, 2018, we amended our Articles of Incorporation (the “Amendment”) to change our name from Newmarkt Corp. to Ozop Surgical Corp. in order to reflect more accurately the name of our core service offering and operations. The Amendment also increased our authorized shares of capital stock to 300,000,000, of which 290,000,000 has been designated as common stock, par value $0.001, and 10,000,000 shares have been designated as preferred stock, par value $0.001 (the “Preferred Stock”). The Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time.

OZOP

OZOP was originally incorporated in Switzerland on November 28, 1998 under the name Perma Consultants Holding AG (“Perma”). On July 19, 2016, Mr. Eric Siu (“Siu”), one of our directors purchased 100% of the outstanding capital stock of Perma and changed the name from Perma to Ozop Surgical AG (“Ozop AG”). On February 1, 2018, Ozop AG was re-domiciled as a Delaware corporation and changed its name to Ozop Surgical, Inc. On July 28, 2016, Ozop formed as the sole member, Ozop Surgical, LLC (“Ozop LLC”), a Wyoming limited liability company. On October 28, 2016, Ozop acquired 100% of Ozop Surgical Limited (“Ozop HK”), from Siu, the sole shareholder of Ozop HK. Ozop HK, a private limited Company incorporated in Hong Kong.

On February 16, 2018, the Company acquired the 100% membership interest (the “Membership Interest”) in Spinus, LLC, a Texas limited liability company (“Spinus”), from RWO Medical Consulting LLC (“RWO”), a Texas limited liability company (the “Acquisition”). The Company purchased the Membership Interest from RWO in exchange for; (i) 5,000,000 shares OZOP’s common stock and ii) the assumption of all liabilities of Spinus, including an obligation of $250,000 pursuant to a license agreement by and between Spinus and a third party (the “Assumed Debt”). The Assumed Debt is secured by Spinus’s assets and is due the earlier of (i) February 16, 2019 or (ii) 15 days subsequent to the Company completing a minimum of a $3,000,000 equity raise. The Company acquired Spinus to gain control of a license rights agreement for exclusive rights to intellectual property related to minimally invasive spine surgery techniques.

The following table summarizes the preliminary value of the consideration issued and the preliminary purchase price allocation of the fair value of assets acquired and liabilities assumed in the acquisition:

	Purchase Price Allocation
Fair value of consideration issued	$	250,000
Liabilities assumed		532,289
Total purchase consideration	$	782,289
Assets acquired	$	543,138
Intellectual Property/Technology		239,151
	$	782,289

The total purchase price of $782,289 has been allocated on a preliminary basis to the tangible and intangible assets acquired and liabilities assumed based on preliminary estimated fair values as of the completion of the Acquisition. These allocations reflect various preliminary estimates that are currently available and are subject to change upon the valuation being finalized within the measurement period. The final fair value of Spinus’s identifiable intangible assets will be determined primarily using the income approach which requires an estimate or forecast of all the expected future cash flows, either through the use of the relief-from-royalty method or the multi-period excess earnings method. The Company will record amortization expense assuming a straight-line basis over the expected life of the finite lived intangible assets, which approximates expected future cash flows.

Goodwill, if any, represents the amount by which the estimated consideration transferred exceeds the historical costs of the assets the Company acquired and the liabilities the Company assumed. The Company will not amortize the goodwill, but will instead test the goodwill for impairment at least annually and whenever events or circumstances have occurred that may indicate a possible impairment.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2018, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2018, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 8-K/A filed on June 29, 2018.

The unaudited condensed consolidated financial statements include the accounts of the Company and Ozop and its’ wholly owned subsidiaries Ozop LLC, Ozop HK and Spinus. Also included in the consolidation is Ozop Medical AG, a company registered in Munich, Germany (“Ozop Medical”). Officers owning approximately 86% of our common stock, own 100% of Ozop Medical. All intercompany accounts and transactions have been eliminated in consolidation.

Emerging Growth Companies

The Company qualifies as an “emerging growth company” under the 2012 JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to take advantage of the benefits of this extended transition period.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits

Accounts Receivable

The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.

Inventory

Inventory is valued at the lower of cost or net realizable value. Cost is determined using the first in first out (FIFO) method. Provision for potentially obsolete or slow-moving inventory is made based on management analysis or inventory levels and future sales forecasts.

Property, plant and equipment

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets. The estimated useful lives of office equipment is 3 years.

Office equipment

The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The Company’s property consisted of the following at June 30, 2018 and December 31, 2017.

	June 30, 2018			December 31, 2017
Office equipment	$	6,885		$	1,944
Less: Accumulated Depreciation		(1,056	)		(621	)
Property and Equipment, Net	$	5,829		$	1,323

Depreciation expense was $273 and $435 for the three and six months ended June 30, 2018, and $162 and $297 for the three and six months ended June 30, 2017.

Patents

Intangible assets primarily represent legal costs and filings associated with obtaining patents on the Company’s new discoveries. The Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life using the straight-line method. The Company tests intangible assets with finite lives upon significant changes in the Company’s business environment and any resulting impairment charges are recorded at that time. When the Company acquires patents from related parties, the patents are recorded at the historical cost when available or the estimated legal and filing costs.

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the three and six months ended June 30, 2018 and 2017.

Advertising and Marketing Expenses

The Company expenses advertising and marketing costs as incurred. For the six months ended June 30, 2018, the Company recorded $35,355 of advertising and marketing expenses, and $954 for the six months ended June 30, 2017.

Research and Development

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the six months ended June 30, 2018, the Company recorded $10,565 of research and development expenses and $41,856 and $84,237 for the three and six months ended June 30, 2017, respectively.

Fair Value of Financial Instruments

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

The following are the hierarchical levels of inputs to measure fair value:

	•	Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
	•	Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	•	Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

The carrying amounts of the Company's financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.

The following table represents the Company’s financial instruments that are measured at fair value on a recurring basis as of June 30, 2018, for each fair value hierarchy level:

June 30, 2018	Derivative Liabilities		Total
Level I	$	—	$	—
Level II	$	—	$	—
Level III	$	659,895	$	659,895

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.

Foreign Currency Translation

The accounts of the Company's Hong Kong subsidiary are maintained in Hong Kong dollars and the accounts of the U.S. companies are maintained in USD. The accounts of the Hong Kong subsidiary were translated into USD in accordance with Accounting Standards Codification ("ASC") Topic 830, Foreign Currency Matters. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders' equity is translated at historical rates and statement of comprehensive income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, Comprehensive Income. Gains and losses resulting from the foreign currency transactions are reflected in the statements of comprehensive income.

Relevant exchange rates used in the preparation of the unaudited condensed financial statements are as follows for the periods ended June 30, 2018 and December 31, 2017 (Hong Kong dollar per one U.S. dollar):

June 30,

2018

December 31,

2017

Balance sheet date

0.1275

0.128

Average rate for unaudited condensed statements of operations and comprehensive loss

0.1276

0.1283

Earnings (Loss) Per Share

The Company computes net loss per share in accordance with FASB ASC 260, “Earnings per Share.” ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period including stock options, using the treasury stock method, and convertible notes and stock warrants, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options, warrants and conversion of convertible notes. Diluted EPS excludes all dilutive potential common shares if their effect is anti-dilutive.

Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)”. Under this guidance, an entity is required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard will have on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805) Clarifying the Definition of a Business” (“ASU 2017-01”). The Amendments in this Update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting, including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those periods. Early adoption of this standard is permitted. The Company adopted ASU 2017-01 on January 1, 2018, with no significant impact on the condensed consolidated financial statements.

With the exception of the new standard discussed above, there have been no other recent accounting pronouncements or changes in accounting pronouncements during the six months ended June 30, 2018, that are of significance or potential significance to the Company.

NOTE 3 – INTANGIBLE ASSETS

Patents as of June 30, 2018 consist of the following:

Patents and trademarks	$	138,934
License rights		500,000
Accumulated amortization		(12,500	)
Net carrying amount	$	626,434

Amortization expense for the three and six months ended June 30, 2018 was $2,206 and $4,412, respectively.

NOTE 4 - CONVERTIBLE NOTES PAYABLE

During the year ended December 31, 2017, OZOP issued 19 convertible promissory notes (the “2017 Notes”), in amounts of $10,000 to $50,000. OZOP received proceeds of $710,000 in the aggregate. The 2017 Notes mature(d) on their one- year anniversary and bear interest at ten percent (10%). The holders can convert the notes and any unpaid interest due, into shares of the Company’s common stock on the 15^th business day that the Company becomes listed, at conversion prices equal to discounts of 35%-50% of the average of the three lowest closing prices of the common stock. OZOP also issued $25,500 of convertible notes for consulting fees. During the six months ended June 30, 2018, the Company issued a $50,000 convertible promissory note (the “March 2018 Note”) and received proceeds of $50,000. The Company determined that the conversion feature of the 2017 Notes and the March 2018 Note (together, the “Notes”) did not meet the criteria of an embedded derivative and therefore the conversion feature was not bi-furcated and accounted for as a derivative because the Company was a private company, there was no quoted price and no active market for the Company’s common stock.

The Company became a public company on April 13, 2018, and on that date the Company determined the conversion feature of the Notes represented an embedded derivative since the Notes were convertible into a variable number of shares upon conversion. Accordingly, on April 13, 2018, the Notes were not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability. Accordingly, the fair value of the derivative instruments of the Notes that occurred prior to April 13, 2018, were recorded as a liability on April 13, 2018, on the unaudited condensed consolidated balance sheet with the corresponding amount recorded as a discount to the Note. Such discount is being amortized from the date of issuance to the maturity dates of the Notes. The change in the fair value of the liability for derivative contracts are recorded in other income or expenses in the unaudited condensed consolidated statements of operations at the end of each quarter, with the offset to the derivative liability on the balance sheet. The embedded feature included in the Notes resulted in an initial debt discount of $620,075, interest expense of $14,000 and initial derivative liability of $634,075. For the six months ended June 30, 2018, amortization of the debt discounts of $398,886 was charged to interest expense. During the six months ended June 30, 2018, investors converted $570,500 of principal and $19,857 of accrued interest into 1,180,768 shares of common stock. Due to the conversions prior to the maturity of the converted notes, the Company recorded additional interest expense and a loss on extinguishment of debt of $234,386. As of June 30, 2018, the outstanding principal balance of the 2017 Notes was $215,000 with a carrying value as of June 30, 2018, of $196,750, net of unamortized discounts of $18,250. The March 2018 Note was part of the above conversions, and the balance of the March 2018 Note as of June 30, 2018 is $-0-.

On April 13, 2018, we issued a convertible promissory note in the principal amount of $442,175 (the “Note”), pursuant to a Securities Purchase Agreement we entered into with an investor dated April 1, 2018. The Note bears interest at the rate of 12% per annum and is due and payable on April 13, 2019. The note is convertible at any time following the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 55% of the average of the lowest trading price for the 25 days prior to conversion. The note was funded on April 13, 2018, when the Company received proceeds of $350,000, after OID of $57,675, and disbursements for the lender’s transaction costs, fees and expenses of $34,500, of which $25,000 were recorded as discounts against the debt to be amortized into interest expense through maturity. Periodic payments are due by us on the Note at the rate of $850 per day (the “Repayment Amount”) via direct withdrawal from our bank account, beginning on April 27, 2018 and to last for a 30-day period. Following this period, the Repayment Amount increased to $1,100 per day until the Note is satisfied in full. On June 28, 2018, the Note was amended to increase the Repayment Amount to $1,750 per day. During the six months ended June 30, 2018, principal payments of $41,800 were made. The embedded conversion feature included in the note resulted in an initial debt discount of $407,675 interest expense of $408,280 and an initial derivative liability of $815,955. For the six months ended June 30, 2018, amortization of the debt discounts of $106,243 was charged to interest expense. As of June 30, 2018, the outstanding principal balance of the note was $400,375 with a carrying value as of June 30, 2018, of $16,268, net of unamortized discounts of $384,107.

We may prepay in full the unpaid principal and interest on the Note, with at least 20 trading days’ notice, (a) any time prior to the 180th day after the issuance date, by paying 130% of the principal amount of the Note together with accrued interest thereon; and (b) any time beginning on the 181st day after the issuance date and ending on the 364th day after the issuance date, by paying 150% of the principal amount of the Note together with accrued interest thereon. After the expiration of the 364th day after the issuance date, we have no right of prepayment.

In connection with our obligations under the Note, our executive officers and the Company entered into a Pledge Agreement (the “Pledge Agreement”) whereby they pledged as collateral for the Loan an aggregate of 19,900,000 shares of our common stock and we pledged the shares of our subsidiary OZOP Surgical, Inc. (collectively, the “Collateral”). Upon a default under the terms of the Note, Carebourn may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease or dispose of the Collateral.

A summary of the convertible note balance as of June 30, 2018 and December 31, 2017 is as follows

	June 30, 2018			December 31, 2017
Principal balance	$	615,375		$	735,500
Unamortized discount		(402,357	)		-0-
Ending balance, net		213,018		$	735,500

NOTE 5 – DERIVATIVE LIABILITIES

The Company valued the derivative liabilities at June 30, 2018, and April 13, 2018, at $659,895 and $1,450,030, respectively. The Company used the Monte Carlo simulation valuation model with the following assumptions as of June 30, 2018; risk-free interest rates from 2.06% to 2.24% and volatility of 121% to 164%, and the following assumptions at April 13, 2018, risk-free interest rates from 1.06% to 1.28% and volatility of 140% to 260%. The initial derivative liabilities for convertible notes issued during the six months ended June 30, 2018, used the following assumptions; risk-free interest rates from 1.89% to 2.29% and volatility of 120% to 331%.

A summary of the activity related to derivative liabilities for the six months ended June 30, 2018, is as follows:

Beginning balance	$	-0-
Issued during period		1,450,030
Converted		(534,666	)
Change in fair value recognized in operations		(255,469	)
Ending balance	$	659,895

NOTE 6 – NOTES PAYABLE

The Company has the following note payables outstanding:

	June 30, 2018
Note payable, interest at 8%, matures September 6, 2018	$	370,000
Note payable, includes $10,000 original issue discount, matures October 30, 2018		60,000
Note payable, interest		230,000
Other, due on demand		2,805
Total notes payable	$	662,805

On June 28, 2018, the Company issued a $230,000 principal amount Promissory note for a purchase price of $200,000 due on August 27, 2018 (the “June 2018 Note”). The June 2018 Note provides for standard and customary events of default such as failing to timely make payments under the June 2018 Note when due. In addition, a default under the June 2018 Note will result in a default under the April 2018 Note (see Note 5). We may prepay in full the unpaid principal on the June 2018 Note. The June 2018 Note also contains customary positive and negative covenants.

NOTE 7 – RELATED PARTY TRANSACTIONS

Management Fees and related party payables

For the three and six months ended June 30, 2018, the Company (including the Company’s subsidiaries) recorded expenses to its officers in the following amounts:

	Three months ended		Six months ended
	June 30, 2018		June 30, 2018
CEO, parent	$	30,000	$	60,000
CEO, subsidiary		30,000		60,000
COO		30,000		60,000
CFO		30,000		60,000
Total	$	120,000	$	240,000

As of June 30, 2018, and December 31, 2017, included in accounts payable and accrued expenses, related party is $404,379 and $220,012, respectively, for the following amounts owed the Company’s officers:

	June 30, 2018		December 31, 2017
CEO, parent	$	80,989	$	46,631
CEO, subsidiary		63,899		-0-
COO		208,905		158,381
CFO		50,586		15,000
Total	$	404,379	$	220,012

NOTE 8 – LICENSE FEE PAYABLE

On February 1, 2018, Spinus entered into an Intellectual Property Licensing Agreement (the “Licensing Agreement”). The Company assumed the obligations under the Licensing Agreement and pledged the assets of Spinus as security. Pursuant to the terms of the Licensing Agreement, in consideration of $250,000 Spinus has the exclusive rights to certain patents and the non-exclusive rights to other patents. The patents surround mechanical or inflatable expandable interbody implant products. The $250,000 is due the earlier of (i) February 16, 2019 or (ii) 15 days subsequent to the Company completing a minimum of a $3,000,000 equity raise. The Company also will pay a royalty of 7% of net sales on any product sold utilizing any of the patents.

NOTE 9 – STOCKHOLDERS’ EQUITY

Common stock

On April 13, 2018, the Company completed the reverse merger with Newmarkt (see Note 1) and issued 2,797,500 shares of common stock. Also on April 13, 2018, the Company purchased and redeemed 2,000,000 shares of common stock for a purchase price of $350,000 pursuant to the Redemption Agreement.

During the six months ended June 30, 2018, we sold 500,000 shares of our common stock at a price of $0.50 per share to seven investors and received proceeds of $250,000.

During the six months ended June 30, 2018, holders of an aggregate of $590,357 in principal and accrued interest of convertible debt issued by OZOP converted their debt and accrued interest into 1,180,768 shares of our common stock at a conversion price of $0.50 per share. These shares have not been certificated and are included in common stock to be issued on the June 30, 2018, balance sheet presented herein.

As of June 30, 2018, the Company has 290,000,000 shares of $0.001 par value common stock authorized and there are 26,297,500 shares of common stock issued and outstanding and 1,180,768 shares of common stock to be issued.

Preferred stock

As of June 30, 2018, 10,000,000 shares have been authorized as preferred stock, par value $0.001 (the “Preferred Stock”), which such Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time. As of June 30, 2018, there are no shares of preferred stock issued and outstanding.

Stock subscription receivable

The Company recorded a stock subscription receivable from its’ officers and directors of $7,600 related to the issuance of 7,600,000 shares of common stock.

NOTE 10 – GOING CONCERN AND MANAGEMENT’S PLANS

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. At June 30, 2018, the Company had a stockholders’ deficit of $1,381,076 and a working capital deficit of $2,013,339. In addition, the Company has generated losses since inception. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern.

Management’s Plans

In April 2018, OZOP entered into and completed a share exchange agreement with Newmarkt Corp., a Nevada corporation (see Note 1), a publicly traded company. As a public company, management believes it will be able to access the public equities market for fund raising for product development and regulatory approvals, sales and marketing and as we expand our distribution in the US market, we will need to meet increasing inventory requirements.

On June 11, 2018, the Company entered into an engagement letter with an Underwriter, with respect to the sale of shares of our preferred stock and warrants to purchase our common stock. Under the terms and subject to the conditions contained in the engagement letter, we have agreed to issue and sell to certain investors through the Underwriter, and the Underwriter has agreed to offer and sell, a minimum of 750,000 and up to 5,000,000 Units, at $2.00 per unit on a best efforts basis. Each Unit consists of one (1) share of Series A 6% Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) and one (1) Common Stock Purchase Warrant (the “Warrants”). Each share of Series A Preferred Stock is entitled to dividends at the rate of 6% per annum, accrued quarterly, is redeemable by the holders three (3) years after issuance and converts into shares of our Common Stock at a rate of $1.00 per share at the option of the holder. Each Warrant entitles the holder to purchase our Common Stock at an exercise price of $1.50 per share for a period of five (5) years after their issuance.

NOTE 11 – SUBSEQUENT EVENTS

On July 23, 2018, the Company, through its wholly owned subsidiary, OZOP (Guangdong) Medical Technology Co., Ltd., a wholly owned foreign enterprise in China, acquired a 100% ownership interest in Yijingtong (Beijing) Technology Development Ltd (“Yijingtong”) from its shareholders who are unrelated parties pursuant to the terms of an Equity Transfer Agreement dated July 23, 2018 (the “Equity Transfer Agreement”). Yijington is a China based distributor of minimally invasive surgical (MIS) products to the orthopedic and neurosurgical markets in China.

Pursuant to the terms of the Equity Transfer Agreement, we agreed to pay the sellers of the Yijingtong equity interest RMB 1,000,000 (approximately US$147,815) payable in cash within 120 days of closing, in addition to inventory valued at RMB 4,072,719 (approximately US$ 602,009), which the parties will separately agree to payment and delivery terms. The sellers of Yijingtong will begin the registration change process upon execution of the Equity Transfer Agreement. In the event either party breaches the agreement, the non-breaching party shall have the right to request termination of the agreement and claim compensation from the breaching party for all economic losses.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This quarterly report and other reports filed by Ozop Surgical Corp. (“we,” “us,” “our,” or the “Company”), from time to time contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used in the filings, the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments, and assumptions. We believe that the estimates, judgments, and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments, and assumptions are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates.

ORGANIZATION

Ozop Surgical Corp. (“the Company”, “we”, “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada, for the purpose of renting out Segways and bicycles. Following the acquisition of OZOP Surgical, Inc. as discussed below, we have been engaged in the business of inventing, designing, developing, manufacturing and globally distributing innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties.

On June 11, 2018, we engaged Advisory Group Equity Services, Ltd., d/b/a RHK Capital (“RHK”), a registered broker-dealer and a member of the Financial Industry Regulatory Authority (“FINRA”), as the underwriter (the “Underwriter”) to sell a minimum of 750,000 Units (each Unit consists of one (1) share of Series A 6% Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) and one (1) Common Stock Purchase Warrant (the “Warrants”) and up to a maximum of 5,000,000 Units (the “Offered Securities”), at a price per Unit of $2.00. Each share of Series A Preferred Stock is entitled to dividends at the rate of 6% per annum, accrued quarterly, is redeemable by the holders three (3) years after issuance and converts into shares of our Common Stock at a rate of $1.00 per share at the option of the holder. Each Warrant entitles the holder to purchase our Common Stock at an exercise price of $1.50 per share for a period of five (5) years after their issuance. The Underwriter will offer the Offered Securities to prospective investors in the United States on a best efforts basis, and our Underwriter will have the right to engage such other broker-dealers or agents as it determines to assist in such offering.

OZOP

On February 16, 2018, OZOP acquired the 100% membership interest (the “Membership Interest”) in Spinus, LLC, a Texas limited liability company (“Spinus”), from RWO Medical Consulting LLC (“RWO”), a Texas limited liability company (the “Acquisition”). OZOP purchased the Membership Interest from RWO in exchange for; (i) 5,000,000 shares OZOP’s common stock and ii) the assumption of all liabilities of Spinus, including an obligation of $250,000 pursuant to a license agreement by and between Spinus and a third party (the “Assumed Debt”). The Assumed Debt is secured by Spinus’s assets and is due the earlier of (i) February 16, 2019 or (ii) 15 days subsequent to the Company completing a minimum of a $3,000,000 equity raise.

RESEARCH AND DEVELOPMENT EXPENDITURES

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with GAAP. For the six months ended June 30, 2018, the Company recorded $10,565 of research and development expenses and $41,856 and $84,237 for the three and six months ended June 30, 2017, respectively.

BANKRUPTCY OR SIMILAR PROCEEDINGS

There has been no bankruptcy, receivership or similar proceeding.

REORGANIZATIONS, PURCHASE OR SALE OF ASSETS

On April 13, 2018, we entered into and completed the Share Exchange Agreement with OZOP, the OZOP Shareholders and Denis Razvodovskij, the holder of 2,000,000 shares of our common stock. Pursuant to the terms of the Share Exchange Agreement, the OZOP Shareholders transferred and exchanged 100% of the capital stock of OZOP in exchange for an aggregate of 25,000,000 newly issued shares of our common stock. The merger was accounted for as a reverse merger, whereby OZOP was considered the accounting acquirer and became a wholly-owned subsidiary of the Company. In accordance with the accounting treatment for a “reverse merger” or a “reverse acquisition,” the Company’s historical financial statements prior to the reverse merger will be replaced with the historical financial statements of OZOP prior to the reverse merger, in all future filings with the SEC. The consolidated financial statements after completion of the reverse merger will include the assets, liabilities and results of operations of the combined company from and after the closing date of the reverse merger.

COMPLIANCE WITH GOVERNMENT REGULATION

Certain of our products will require approval from the Food and Drug Administration (the “FDA”) in the United States and similar agencies in China (the “CFDA”) and Europe (the “CE”). The Company’s endoscopes will be classified as Class II devices in the United States. Class II devices require either approval or clearance from the FDA before they can be marketed in the United States. Products that have substantial similarity to products that already have been approved by the FDA can obtain clearance for marketing through the Premarket Notification process under Section 510K of the FD&C Act. This process typically takes 6-9 months and costs approximately $300,000. Concurrently, the Company is exploring ways to accelerate FDA approval either through expedited applications or co-branding with FDA approved suppliers. This is aided by the fact that our suppliers in Germany are currently both FDA and CE certified.

FACILITIES

We currently utilize the office of our CFO, in West Palm Beach, Florida for our corporate and administrative purposes at no charge to the Company.

EMPLOYEES AND EMPLOYMENT AGREEMENTS

Other than our officers and directors we have no employees. We do not have formal agreements with our four officers and directors, however, the Company has been accruing $10,000 per month for each.

LEGAL PROCEEDINGS

There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Our April 13, 2018 acquisition of OZOP was accounted for as a reverse merger, whereby OZOP was considered the accounting acquirer and became a wholly-owned subsidiary of the Company. In accordance with the accounting treatment for a “reverse merger” or a “reverse acquisition,” the Company’s historical financial statements prior to the reverse merger will be replaced with the historical financial statements of OZOP prior to the reverse merger. The consolidated financial statements after completion of the reverse merger will include the assets, liabilities and results of operations of the combined company from and after the closing date of the reverse merger.

Results of Operations for the three and six months ended June 30, 2018 and 2017:

Revenue

For the three and six months ended June 30, 2018, the Company generated total revenue of $105,763 and $117,690, respectively, compared to $43,893 and $56,771 for the three and six months ended June 30, 2017, respectively. The revenues are from the sale of spine surgery products and endoscopes. The increase in revenues is a result of revenues of $60,910 and $72,837 for the three and six months ended June 30, 2018, respectively from Spinus. Spinus was acquired in February 2018 and therefore there were no revenues in the 2017 periods from Spinus.

Cost of goods sold

For the three and six months ended June 30, 2018, cost of goods sold was $63,628 and $68,828, respectively, compared to $29,145 and $38,870 for the three and six months ended June 30, 2017, respectively. The increase in cost of goods sold is a result of the increase in sales revenue described above.

Operating expenses

Total operating expenses for the three and six months ended June 30, 2018, were $271,312 and $508,794, respectively, compared to $228,750 and $552,232 for the three and six months ended June 30, 2017, respectively. The operating expenses were comprised of:

	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
Management fees	$	120,000	$	90,000	$	240,000	$	180,000
Professional and consulting fees		53,763		48,860		101,164		143,751
Research and development		—		41,856		10,565		84,237
General and administrative		97,549		48,034		157,065		144,244
Total	$	271,312	$	228,750	$	508,794	$	552,232

The increase in operating expenses is a result of the Company engaging a CFO in 2018 and incurring expenses of $30,000 and $60,000 for the three and six months ended June 30, 2018, respectively. Additionally, Spinus’s general and administrative expenses for the three and six months ended June 30, 2018, of $17,408 and $36,775, respectively, are included in the 2018 periods.

Other Income (Expenses)

Other expenses, net, for the three and six months ended June 30, 2018 was $378,068 and $406,615, respectively, compared to other expenses, net, of $8,869 and $13,719, respectively, for the three and six months ended June 30, 2017.

	Three months ended June 30,					Six months ended June 30,
	2018			2017		2018			2017
Interest expense	$	460,135		$	8,869	$	488,682		$	13,719
Gain on change in fair value of derivatives		(255,469	)		—		(255,469	)		—
Amortization of debt discounts		473,682			—		473,682			—
Gain on extinguishment of debt		(300,280	)		—		(300,280	)		—
Total other expense (income), net	$	378,068		$	8,869	$	406,615		$	13,719

The increase in other income (expense) is primarily a result of an increase in gain on extinguishment of debt and change in fair value of derivatives partially offset by an increase in interest expense and amortization of debt discounts.

Net loss

The net loss for the three and six months ended June 30, 2018 was $607,244 and $866,547 respectively, compared to $222,871 and $548,050 for the three and six months ended June 30, 2017, respectively. The increases are a result of the changes discussed above.

Liquidity and Capital Resources

Currently, we have limited operating capital. The Company anticipates that it will require a minimum of $1,500,000 of working capital to complete substantially all of its desired business activity for the next twelve months. The Company has earned limited revenue from its business operations. Our current capital and our other existing resources will be sufficient only to provide a limited amount of working capital, and, to date, the revenues generated from our business operations have not been sufficient to fund our operations or planned growth. As noted above, we will likely require additional capital to continue to operate our business, and to further expand our business. We may be unable to obtain the additional capital required. Our inability to generate capital or raise additional funds when required will have a negative impact on our operations, business development and financial results.

For the six months ended June 30, 2018, we primarily funded our business operations with $600,000 of proceeds from the issuance of a note payable ($230,000) and convertible note financings ($492,175) as well as $250,000 from the sale of 500,000 shares of common stock at $0.50 per share. Of the proceeds $350,000 was used to redeem 2,000,000 shares of common stock from our former CEO and funded our business operations and were also used to make payments on convertible debt of $41,846. We are conducting a private placement offering to seek to raise the necessary working capital to continue to fund our business operations, or we may continue to rely on the issuance of convertible promissory notes to fund our business operations. We have engaged RHK, on a best effort basis to raise a minimum of $1,500,000 to a maximum of $10,000,000, to provide working capital and debt payments.

As of June 30, 2018, we had cash of $275,412, as compared to $110,792 at December 31, 2017. As of June 30, 2018, we had current liabilities of $2,641,754 (including $659,895 of non-cash derivative liabilities), compared to current assets of $628,235, which resulted in a working capital deficit of $2,013,339. The current liabilities are comprised of accounts payable, accrued expenses, convertible debt, derivative liabilities, license fees payable and notes payable.

Operating Activities

For the six months ended June 30, 2018, net cash used in operating activities was $310,746, compared to $302,060 for the six months ended June 30, 2017. For the six months ended June 30, 2018, our net cash used in operating activities was primarily attributable to the net loss of $866,547, the gain on the change in fair value of derivative liabilities and the gain in extinguishment of debt, adjusted by the non-cash expenses of interest and amortization and depreciation of $900,809. Net changes of $201,241 in operating assets and liabilities reduced the cash used in operating activities. For the six months ended June 30, 2017, our net cash used in operating activities was primarily attributable to the net loss adjusted by the net changes of $243,910 in operating assets and liabilities.

Investing Activities

For the six months ended June 30, 2018, cash provided by investing activities of $16,639 was comprised of the cash acquired in the Spinus acquisition of $21,580, offset by the purchase of office equipment of $4,941. For the six months ended June 30, 2017, the Company purchased office equipment of $1,944.

Financing Activities

For the six months ended June 30, 2018, the net cash provided by financing activities was $458,154, compared to $250,000 for the six months ended June 30, 2017. During the six months ended June 30, 2018, we received $600,000 of proceeds from the issuance of a note payable ($230,000) and convertible note financings ($492,175) as well as $250,000 from the sale of 500,000 shares of common stock at $0.50 per share. Payments of $350,000 was used to redeem 2,000,000 shares of common stock from our former CEO and we also made payments on convertible debt of $41,846. The net cash provided by financing activities of $250,000 for the six months ended June 30, 2017, resulted from proceeds of $50,000 from the issuances of convertible notes and $200,000 from the issuance of notes payable.

OFF BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support or other benefits.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not Applicable.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the "Exchange Act"), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of June 30, 2018. Based on the evaluation of these disclosure controls and procedures, and in light of the material weaknesses found in our internal controls over financial reporting, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective for the reasons discussed below.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting as of June 30, 2018, the Company determined that there were control deficiencies that constituted material weaknesses, as described below.

1.	We do not have an Audit Committee – While not being legally obligated to have an audit committee, it is the management’s view that such a committee, including a financial expert member, is an utmost important entity level control over the Company’s financial statement. Currently the Board of Directors acts in the capacity of the Audit Committee, and does not include a member that is considered to be independent of management to provide the necessary oversight over management’s activities.

2.	We did not maintain appropriate cash controls – As of June 30, 2018, the Company has not maintained sufficient internal controls over financial reporting for cash, including failure to segregate cash handling and accounting functions, and did not require dual signatures on the Company’s bank accounts.

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.

Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

Changes in Internal Controls over Financial Reporting

There has been no change in our internal control over financial reporting occurred during the three months ended June 30, 2018, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.

LEGAL PROCEEDINGS

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

Item 1A.

RISK FACTORS

Not applicable.

Item 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the six months ended June 30, 2018, we sold 500,000 shares of our common stock at a price of $0.50 per share to seven investors and received proceeds of $250,000.

The shares of Common Stock issued to the investors in this offering were issued in reliance upon the exemption from securities registration afforded by the provisions of Section 4(a)(2) of the Securities Act of 1933, as amended, (“Securities Act”), and/or Regulation D, as promulgated by the U.S. Securities and Exchange Commission under the Securities Act.

During the six months ended June 30, 2018, holders of an aggregate of $590,384 in principal and accrued interest of convertible debt issued by OZOP converted their debt and accrued interest into 1,180,768 shares of our common stock at a conversion price of $0.50 per share. These shares have not been certificated and are included in common stock to be issued on the June 30, 2018, balance sheet presented herein.

The issuances described above related to the conversion of debt were made in reliance on the exemption from registration provided by Sections 3(a)(9) of the Securities Act as the common stock was issued in exchange for debt securities of the Company held by each shareholder, there was no additional consideration for the exchange, there was no remuneration for the solicitation of the exchange, the shareholders were not affiliates, and they had held the underlying debt securities for a long time.

Item 3.

DEFAULTS UPON SENIOR SECURITIES

None.

Item 4.

MINE SAFETY DISCLOSURE

Not applicable to our Company.

Item 5.

OTHER INFORMATION

None.

Item 6.

EXHIBITS

The following exhibits are included as part of this report by reference:

Exhibit No.	Description

2.1		Share Exchange Agreement dated April 5, 2018 by and among Newmarkt Corp., the shareholders of Ozop Surgical, Inc., Ozop Surgical, Inc. and Denis Razvodovskij (Incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed on April 19, 2018).

3.1		Articles of Incorporation (incorporated by reference to our General Form for Registration of Securities on Form S-1 filed on August 1, 2016)

3.2		Bylaws (incorporated by reference to our General Form for Registration of Securities on Form S-1 filed on August 1, 2016)

3.3		Certificate of Amendment of Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on May 8, 2018 (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on May 14, 2018).

10.1		Share Redemption Agreement dated April 13, 2018, by and between Newmarkt Corp. and Denis Razvodovskij (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on April 19, 2018).

10.2		Securities Purchase Agreement dated April 13, 2018, by and between Newmarkt Corp. and Carebourn Capital, L.P. (Incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed on April 19, 2018).

10.3		$442,175 Convertible Promissory Note dated April 13, 2018, by Newmarkt Corp. in favor of Carebourn Capital, L.P. (Incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed on April 19, 2018).

10.4		Form of Pledge Agreement in favor of Carebourn Capital, L.P. (Incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K filed on April 19, 2018).

10.5		$230,000 Promissory Note dated June 28, 2018 by Ozop Surgical Corp. in favor of Carebourn Capital, L.P. (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on July 5, 2018).

10.6		Amendment to Convertible Promissory Note dated June 28, 2018 to $442,175 Convertible Promissory Note dated April 13, 2018, by Ozop Surgical Corp. in favor of Carebourn Capital, L.P. (Incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed on July 5, 2018).

10.7		Equity Transfer Agreement entered into among Zhao Zhen Rong, Sun Gui Ying and OZOP (Guangdong) Medical Technology Co., Ltd. dated July 23, 2018 (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on July 23, 2018)..

10.8*		Intellectual Property Portfolio License Agreement dated February 1, 2018 by and between Loubert S. Suddaby, MD and Spinus, LLC.

31.1*			Certification of Chief Executive Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*			Certification of Chief Financial Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*			Certification of Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

101.INS**			XBRL Instance Document

101.SCH**			XBRL Taxonomy Extension Schema Document

101.CAL**			XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF**			XBRL Taxonomy Extension Definition Linkbase Document

101.LAB**			XBRL Taxonomy Extension Label Linkbase Document

101.PRE**			XBRL Taxonomy Extension Presentation Linkbase Document

____________

* Filed Herewith

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 20, 2018

OZOP SURGICAL CORP.

By: /s/ Michael Chermak

Michael Chermak

Chief Executive Officer (principal executive officer)

By: /s/ Barry Hollander

Barry Hollander

Chief Financial Officer (principal financial and accounting officer)

EX-10.8 2 ozsc0818form10qexh10_8.htm EXHIBIT 10.8

Exhibit 10.8

Intellectual Property Portfolio License Agreement

This agreement, dated as of February 1,2018 (the “Effective date”) is by and between Loubert S. Suddaby, MD (“Licensor”) and Spinus, LLC (hereinafter referred to as the “ Company”), collectively hereinafter referred to as the “Parties” and each hereinafter referred to a “Party”).

Now therefore, in consideration of mutual promises, agreements, covenant, undertakings and obligations set forth herein and for other good and valuable consideration, the Parties hereto agree as follows:

ARTICLE 1 – DEFINITIONS

1.1

Definitions. For the purpose of the Agreement, the definitions set forth below shall be applicable.

Affiliate – The term “Affiliate” means with respect to any person or entity, any other person or entity directly or indirectly controlling, controlled by, or under common control with, such person or entity at any time during the period for which the determination of affiliation is being made. For purposes of the foregoing, “control” means that more than fifty percent (50%) of the outstanding shares of any voting class of stock, general partnership interest or other voting equity or analogous interests of the one entity is owned by another entity, or the existence of any other relationship between two entities which results in the direct or indirect effective managerial control by one over the other, regardless of whether such managerial control is continuously exercised.

Applicable Law – The term “Applicable Law” means all laws, ordinances, rules and regulations applicable to the Agreement of the activities contemplated hereunder.

Assigned Patents – The term “Assigned Patents” means U.S. and foreign patents, patent applications and provisional patent applications pertaining to EXHIBIT A.

Consulting Agreement – The term “Consulting Agreement” refers to the agreement between Licensor and the Company pursuant to which the Licensor agrees to provide Services (as defined therein) to the Company in connection the Company’s efforts to develop ratcheting expandable interbody fusion devices, and/or inflatable interbody fusion devices.

First Commercial Sale – The term “First Commercial Sale” shall mean the first arm’s length sale by the Company and/or Company Affiliate to a third party.

Licensed Patents – The term “Licensed Patents” means the U.S. and foreign patents, patent applications and provisional patent applications listed on Exhibit A hereto, and all continuations, continuations-in-part, divisions reissues and reexaminations of any of the foregoing, and any patents that claim priority to any of them, and any patents which are or become foreign equivalents thereof.

Net Sales – The term “Net Sales” for any period means gross sales of the product billed and shipped by the Company or its Affiliate anywhere in the world, less given discounts.

Products – The term “Product” or “Products” means mechanical or inflatable expandable interbody implants covered by a Licensed Patent or Assigned Patent.

Valid Claim – The term “Valid Claim” means a claim of a patent duly issued which has not been declared invalid or unenforceable in a final judgment from which no appeal may be taken.

ARTICLE 2 – THE GRANT

2.1 Grant. Subject to the terms and conditions hereof, Licensor hereby grants to the Company and its Affiliates, and the Company hereby accepts a worldwide nontransferable license, royalty bearing right and license under the licensed Patents to evaluate, develop, test, conduct clinical, trials, obtaining government approvals, make, have made, use, practice manufacture, have manufactured, sell, transfer or commercialize products with the understanding that such rights to products listed in Section 2 of Exhibit A are exclusive whereas these rights are non-exclusive with respect to products set out in Section 1 of Exhibit A. Except as explicitly granted herein, no rights are granted herein by implication, estoppel or otherwise and all rights not explicitly granted are reserved.

2.2 Commercialization. If the Company fails within three (3) years from the Effective Date for any reason other than delays due to regulatory review authorities to sell Products, Licensor may, at its option, terminate the Agreement and the licenses granted herein by providing the Company with notice of termination, which termination shall be effective immediately upon receipt.

2.3 Limitations and Obligations

(a) neither Licensor nor the Company may, without consent of the other, act as a supplier of products to another party where such products are to be labelled for sale under any name other than Licensor or the Company or their respective Affiliates.

(b) Obligation of Affiliates. The Company agrees that it is legally and financially responsible for its obligations and the obligations of its Affiliates arising under this Agreement.

ARTICLE 3 – CONSIDERATION

3.1 Consideration. The Parties have entered this Agreement voluntarily, and as a matter of convenience have agreed that the total consideration to be paid by the Company for the rights granted hereunder shall be the following.

(a) Royalties on Net Sales of the Products occurring during the term of this Agreement, at a rate of seven per cent (7%) of such Net Sales.

(b) Royalties pursuant to Section 3.1 (a) shall be for the life of the Product and shall be paid as long as said Product is sold by the Company or its Affiliates.

(c) In addition, the Company will pay the following license fees (“License Fees”) which will be non-refundable and not credited against any Royalties due under this Agreement.

(d) Two hundred fifty thousand dollars ($250,000) within one year of signing the Agreement.

The Parties represent and warrant that in entering into this Agreement they have bargained at arm’s length, that the amounts paid hereunder or set in advance and are fair market value for the services provided.

3.2 Royalty Accrual. Royalties pursuant to 3.1 shall accrue as when the Net Sale subject to such royalty is recorded by the Company, or its Affiliates, in accordance with the definition of “Net Sale” and shall be paid to the Licensor in accordance with the provisions of Article 4 below.

ARTICLE 4 – REPORTS, PAYMENTS AND RECORDS

4.1 Reports. The Company agrees to deliver quarterly written reports to Licensor for each quarterly period for which Royalties are payable pursuant to Article 3 above, within thirty (30) days after the end of each period. The report shall set forth the number of products sold by the Company or its Affiliates during such quarterly period, as determined by the Company in good faith, and, based and thereon, the calculation and amount of Royalties payable to the Licensor with respect to such period pursuant to Article 3. All information contained in such quarterly reports shall be treated as confidential by the Company subject to Article 5 and shall be subject to adjustment, pursuant to section 4.2 below, based upon any Examination and the results of the Company’s regular annual audit.

4.2 Payment and Records. Royalties payable pursuant to Section 3.1 above for a reported period shall be due and payable, to the extent calculated and set forth in the corresponding quarterly report delivered to Licensor pursuant to Section 4.1 simultaneously with the submission of such report. The full amount of all Royalties, when due, shall be paid to Licensor by certified check or bank transfer. In order to enable an independent certified public accounting firm (the “CPA Firm”) appointed by Licensor and reasonably acceptable the Company to verify the proper determination of Royalties, the Company shall maintain records in sufficient detail to allow for such verification, and, subject to Article 5 below and upon reasonable notice, allow the CPA Firm to examine the Company consolidated books and records, and to the extent necessary the books and records of its Affiliates pertaining to Product sales subject to the Company Royalty obligations hereunder (such examination, the “Examination”). Examinations shall occur during business hours, and not more than once a year, and shall be solely for the purpose of verifying the calculation of Royalties due under the Agreement. The CPA Firm shall furnish a copy of any Examination results to Licensor and the Company promptly after completion thereof, together with all work papers. Any underpayment of Royalties due to Licensor will be rectified in thirty (30) days. The Company shall pay the reasonable costs, fees and expenses of the CPA Firm that may otherwise be due and payable by the Licensor to the CPA Firm for an examination conducted by it pursuant to this Section 4.2, if and only if as a result of such Examination it is determined that the Company underpaid the total amount due to the Licensor, applicable to the period that was the subject of such Examination by more than five percent (5%).

4.3 Late Payments. In the event that any amount payable under this Agreement is not paid when due, the Company will also pay interest on such amount for the period from the date the payment is actually made computed at the rate equal to two percent (2%) per month.

ARTICLE 5 – PROPRIETARY INFORMATION

5.1 Confidentiality. During the term of this Agreement and for an additional five (5) years, each Party agrees to keep and maintain the terms of this Agreement confidential, and to keep confidential and use solely insofar as permitted by the express terms of this Agreement any other non-public information disclosed to or obtained from such Party by the other Parties in connection with this Agreement. Notwithstanding the foregoing, it shall not be a breach of this Agreement (i) in the event an action by one Party is believed by the other Party to be in breach of this Agreement, for the other Party to file under seal with the court in such action such terms of this Agreement as are necessary in order to bring or defend such action, (ii) for each Party to share the terms of this Agreement with its counsel, provided such counsel is or has been made aware of the obligations of confidentiality herein, (iii) for any Party to disclose such information as may be required by law or court order, after first having given the other Party at least ten (10) days written notice of such legal requirement or order of court and intent to disclose pursuant to said requirement or order and (iv) for each Party to share the terms of this Agreement with any of its Representatives (as defined below), as such party reasonably deems necessary based on a “need to know” assessment, provided that the disclosing Party prior to disclosure, shall obtain a binding agreement of such Representatives requiring them to retain the disclosed terms in confidence according to confidentiality obligations that are at least as stringent as those imposed herein. In the event of a breach of such agreement by a disclosing Party’s Representatives, the other Party may request that such disclosing Party, at its expense, initiate and prosecute judicial proceedings to enforce such agreement, to the extent there is a legally cognizable good faith basis to do so, and seek damages and injunctive relief as may be suitable and subject to recovery, or assign to the other Party the right, at its expense, to pursue such enforcement, damages and relief, and the disclosing Party shall comply with any such request. The term “Representative” includes a Party’s and its Affiliates’ respective directors, officers, employees, agents, financial advisors, attorneys, insurers, accountants and permitted assignees and sublicensees.

5.2 Survival. The provisions of this Article 5 shall survive expiration or termination of this Agreement.

ARTICLE 6 – REGULATORY INTERACTION AND INDEMIFICATION

6.1 Regulatory Interaction. Interaction with regulatory agencies in any country, including but not limited to the FDA and any international regulatory agencies, concerning Products manufactured or sold by the Company or its Affiliates shall be a matter for the sole discretion of, and shall be conducted by or with authority from, the Company or its Affiliates.

6.2 Indemnification.

(a) subject to the fulfillment by Licensor of its obligations pursuant to Section 6.3 below, the Company agrees to defend, indemnify and hold harmless Licensor, its Affiliates and their respective officers, directors, employees, agents and representatives (collectively, “Licensor Indemnities,” and each a “Licensor Indemnitee” from and against all damages, liabilities, claims (including, without limitation, product liability claims), costs, charges, judgements and expenses (including reasonable attorneys’ fees and expenses incurred by the Company in asserting such defense, but otherwise excluding fees and expenses incurred by the Company in asserting such defense, but otherwise excluding fees and costs of attorneys retained by Licensor or any foregoing Licensor Indemnitee) (collectively, “Liabilities”), to the extent such Liabilities are asserted against a Licensor Indemnitee by a third party and arise out of or result from (i) a defect in the design or manufacture of a Product sold or otherwise distributed by the Company or its Affiliates or (ii) sale or promotion of such a Product by the Company or its Affiliates, or (iii) a breach of any representation or warranty given to Licensor by the Company pursuant to this Agreement; or (iv) a third party claim that the manufacture, use, sale, offer for sale or importation of the Product infringes upon the patent of such a third party by reason of the Company’s exercise of any of the rights granted by Licensor under this Agreement and in accordance with this Agreement;

(b) subject to the fulfillment by the Company of its obligations pursuant to Section 6.3 below, Licensor agrees to defend, indemnify and hold harmless the Company, its Affiliates and their respective officers, directors, employees, agents and representatives (collectively, the “Company Indemnities”, and each a Company Indemnitee, from and against all damages, liabilities, claims (including, without limitation, product liability claims), costs, charges, judgements and expenses (including reasonable attorney’s fees and expenses incurred by Licensor in asserting such defense, but otherwise excluding fees and costs of attorneys retained by the Company or any foregoing Company Indemnitee) (collectively “Liabilities”), to the extent such Liabilities are asserted against the Company Indemnitee by a third party and arise out of or result from (i) a defect in the design or manufacture of a Product sold or otherwise distributed by Licensor or its Affiliates or sublicensee through Licensor’s exercise of his rights hereunder, or (ii) sale or promotion of such a Product by Licensor or its Affiliates, or sublicensee, or (iii) a breach of any representation or warranty given to the Company by Licensor pursuant to this Agreement; or (iv) a third party claim that the manufacture, use, sale, offer for sale or importation of the Product by Licensor or its Affiliates infringes upon the patent of such a third party.

6.3 Consequential Damages. IN NO CASE, HOWEVER WHETHER AS A RESULT OF A BREACH OF CONTRACT, BREACH OR WARRANTY OR TORT (INCLUDING THE COMPANY’S OR LICENSOR’S NEGLIGENCE OR STRICT LIABILITY) SHALL THE COMPANY OR LICENSOR BE LIABLE TO THE OTHER FOR

ANY SPECIAL, CONSEQUENTIAL OR INCIDENTAL DAMAGES INCURRED BY THE OTHER, INCLUDING BUT NOT LIMITED TO ANY LOSS OF USE, INTERRUPTION OF BUSINESS, INJURY TO GOODWILL, OR LOSS OF SALES OR LOST PROFITS.

ARTICLE 7 – REPRESENTATIONS AND WARRANTIES

7.1 Representations and Warranties. Each Party hereby represents and warrants to the other Party that

(a) he or it has full right, power and authority to enter into and be bound by the terms and conditions of this Agreement, to transfer the rights and to carry out their respective obligations under this Agreement, without the approval or consent of any other person, (b) the entering into this Agreement, the transfer of rights and the carrying out of their respective obligations under this Agreement is not prohibited, restricted or otherwise limited by any contract, agreement or understanding entered into by such Party, or by which such Party is bound, with any other person, including without limitation, any governmental authority, (c) there is no contract, agreement or understanding entered into by a Party, or by which such Party is bound, which is enforced, terminated or modified, would be in derogation or, contrary to, or adversely affect the rights acquired or to be acquired by the other party hereunder, and (d) there is no action or investigation pending or currently threatened against such Party which, if adversely determined, would restrict or limit such Party’s right to enter into this Agreement, transfer the rights or carry out such Party’s obligations under this Agreement. Licensor further represents and warrants that: (i) he is the sole and exclusive beneficial and legal owner of all right, title and interest in the Licensed Patents listed in Exhibit A, (ii) the Licensed Patents listed in Exhibit A are all the patents and applications owned by Licensor relating to the expandable intervertebral interbody fusion implants and all patents and applications owned by Licensor relating to inflatable expandable interbody fusion implants; (iii) the Licensed Patents listed in Exhibit A name the true and correct inventive entity (iv) the licensed or assigned patents listed in Exhibit A name the products to be assigned or licensed in their entirety and this agreement in no way impugns or impedes the Licensor’s right to continue to invent, patent, make, license or sell other devices or products not expressly listed in Exhibit A, even if such products are deemed competitive so long as they are independent patents with distinct valid claims.

ARTICLE 8 – TERM AND TERMINATION

8.1 Term. The term of this Agreement (the “Term”) shall commence upon the date hereof and shall continue until the last date upon which Product sale ceases and all reasonably collectible Net Sales have been received. If, however, at any time either Party (the “Breaching Party”) shall fail to comply in any material respect with any of the obligations hereunder, the other Party (the “Other Party”)may terminate this Agreement upon thirty (30) days prior written notice of the Breaching Party, if such failure is not cured within thirty (30) days after such notice, provided that, if such cure cannot be accomplished within thirty (30) day period no such termination shall result and the period for such cure shall be extended as long as the Breaching Party is diligently pursuing a cure thereof.

8.2 Reservation of Rights. The Parties expressly reserve all rights and remedies at law and specifically but without limitation damages, injunctive and other provisional relief.

ARTICLE 9 – RIGHTS AFTER TERMINATION

9.1 Rights After Termination.

(a) All obligations of the Parties which accrue on or before the effective termination date shall be fully enforceable after termination.

(b) If this Agreement terminates and as a result, thereof, the Company is required to cease making Products covered by the Licensed Patents, the Company, may nonetheless, subject to the royalty provisions set forth herein, dispose of inventory of Products, complete any Products in the process of manufacture, and utilize materials then on order to make and sell Products.

ARTICLE 10 – NOTICES

10.1 Notices. Any notice required or permitted to be given hereunder shall be in writing and shall be mailed by certified mail, return receipt requested or delivered by messenger or air courier (overnight fare prepaid), and all payments shall be delivered, to the party to whim such notice or payment is required or permitted to be given at its address set forth as follows:

If given to Licensor, to:

Loubert S. Suddaby

76 Tanglewood Drive West

Orchard Park, NY 14127

Email: loubert57@gmail.com

Or, if given to the Company, to:

Spinus LLC

5227 W. Adams Ave, Apt 401

Temple,TX 76502-4853

Attention: Ron Oman

Email: Ron@spinusllc.com

Any such notice shall be considered when delivered, as indicated by signed receipt or other written delivery record, and absent such receipt, or record, such delivery shall be deemed to have occurred one business day after sending by messenger or courier and five business days after sending by certified mail. A Party hereto may change that address to which notice to it is to be given by notice as provided herein.

ARTICLE 11 – GOVERNING LAW – ATTORNEY’ FEES

11.1 Governing Law and Forum. This Agreement shall be construed and enforced in accordance with the internal laws of the State of Delaware.

11.2 Attorneys’ Fees. In any action brought by either Party against the other to enforce this Agreement, the prevailing party shall be entitled to reimbursement of all costs and expenses (including reasonable attorneys’ fees) incurred in connection with such enforcement action.

11.3 Patent Maintenance Fees. The company agrees to pay all costs pertinent to the maintenance of the licensed or assigned patents.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

Loubert S. Suddaby, MD		Spinus LLC



_________________________		BY:______________________
		Ron Oman, Manager

EXHIBIT A

1. LICENSED PATENTS (NON-EXCLUSIVE)

1.1 RATCHETING EXPANDABLE TECNOLOGY

PATENT NUMBER	TITLE	STATUS

7,044,971	Lordotic Fusion Implant	Issued
US52206/0167547	Expandable Intervertebral Fusion Implant Having Hinged Walls	Pending
6,183,517	Expandable Fusion Implant and Applicator	Issued
6,174,334	Expandable Intervertebral Fusion Implant and Applicator	Issued
6,159,244	Expandable Variable Angle Intervertebral Fusion Implant	Issued
6,332,895	Expandable Intervertebral Fusion Implant Having Improved Stability	Issued
EP 1139936	Expandable Intervertebral Fusion Implant	Issued
EP 1301149	Expandable Intervertebral Fusion Implant Having Improved Stability	Issued

1.2 RACHETING CERVICAL TECNOLOGY

PATENT NUMBER	TITLE	STATUS

6,328,738 B1	Anterior Cervical Fusion Compression Plate and Screw Guide	Issued

1.3 MIS (MINIMALLY INVASIVE SURGERY) FACET FIXATION DEVICE

PATENT NUMBER	TITLE	STATUS

8,080,046 B2	Facet Joint Fixation Device	Issued
8,915,962 B1	Facet Joint Fixation Device	Issued

2. LICENSED PATENTS (EXCLUSIVE)

PATENT NUMBER	TITLE	STATUS

6,837,850 B2	Percutaneous Tissue Dissection	Issued
6,958,077 B2	Inflatable Nuclear Prosthesis	Issued
6,969,405 B2	Inflatable Intervertebral Disc Replacement Prosthesis	Issued
7,597,714 B2	Inflatable Nuclear Prosthesis	Issued
7,914,534 B2	Disk Preparation Tool	Issued
6,395,034 B1	Intervertebral Disc Prosthesis	Issued

EX-31.1 3 ozsc0818form10qexh31_1.htm EXHIBIT 31.1

EXHIBIT 31.1

Certification of Chief Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934

I, Michael Chermak, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018 of OZOP SURGICAL CORP. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b) Designed such internal control over financing reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 20, 2018

/s/ Michael Chermak

Michael Chermak, Chief Executive Officer

(Principal Executive Officer)

EX-31.2 4 ozsc0818form10qexh31_2.htm EXHIBIT 31.2

EXHIBIT 31.2

Certification of Chief Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934

I, Barry Hollander, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018 of OZOP SURGICAL CORP. (the “registrant”);

	(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b) Designed such internal control over financing reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 20, 2018

/s/ Barry Hollander

Barry Hollander

Chief Financial Officer

(principal financial and accounting officer)

EX-32.1 5 ozsc0818form10qexh32_1.htm EXHIBIT 32.1

EXHIBIT 32.1

Certification of Periodic Financial Report by the Chief Executive Officer and

Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of OZOP SURGICAL CORP. (the “Company”) for the quarterly period ended June 30, 2018 as filed with the Securities and Exchange Commission (the “Report”), I, Michael Chermak, Chief Executive Officer and I, Barry Hollander, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

1. The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 20, 2018	/s/ Michael Chermak
	Michael Chermak Chief Executive Officer

Date: August 20, 2018	/s/ Barry Hollander
	Barry Hollander Chief Financial Officer

EX-101.INS 6 ozsc-20180630.xml XBRL INSTANCE FILE 0001679817 2018-01-01 2018-06-30 0001679817 2018-08-14 0001679817 2018-06-30 0001679817 2017-12-31 0001679817 2018-04-01 2018-06-30 0001679817 2017-04-01 2017-06-30 0001679817 2017-01-01 2017-06-30 0001679817 2016-12-31 0001679817 2017-06-30 0001679817 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2018-01-01 2018-06-30 0001679817 OZSC:SeriesOfIndividuallyImmaterialBusinessAcquisitions2Member 2018-01-01 2018-06-30 0001679817 2018-04-13 0001679817 2018-02-16 0001679817 us-gaap:FairValueInputsLevel1Member 2018-06-30 0001679817 us-gaap:FairValueInputsLevel2Member 2018-06-30 0001679817 us-gaap:FairValueInputsLevel3Member 2018-06-30 0001679817 currency:HKD 2018-06-30 0001679817 currency:HKD 2017-12-31 0001679817 OZSC:HKD1Member 2018-06-30 0001679817 OZSC:HKD1Member 2017-12-31 0001679817 2018-06-29 2018-06-30 0001679817 2018-04-12 2018-04-13 0001679817 us-gaap:ChiefExecutiveOfficerMember 2018-04-01 2018-06-30 0001679817 us-gaap:ChiefExecutiveOfficerMember 2018-01-01 2018-06-30 0001679817 srt:AffiliatedEntityMember 2018-04-01 2018-06-30 0001679817 srt:AffiliatedEntityMember 2018-01-01 2018-06-30 0001679817 us-gaap:ChiefOperatingOfficerMember 2018-04-01 2018-06-30 0001679817 us-gaap:ChiefOperatingOfficerMember 2018-01-01 2018-06-30 0001679817 us-gaap:ChiefFinancialOfficerMember 2018-04-01 2018-06-30 0001679817 us-gaap:ChiefFinancialOfficerMember 2018-01-01 2018-06-30 0001679817 us-gaap:ChiefExecutiveOfficerMember 2018-06-30 0001679817 us-gaap:ChiefExecutiveOfficerMember 2017-12-31 0001679817 srt:AffiliatedEntityMember 2018-06-30 0001679817 srt:AffiliatedEntityMember 2017-12-31 0001679817 us-gaap:ChiefOperatingOfficerMember 2018-06-30 0001679817 us-gaap:ChiefOperatingOfficerMember 2017-12-31 0001679817 us-gaap:ChiefFinancialOfficerMember 2018-06-30 0001679817 us-gaap:ChiefFinancialOfficerMember 2017-12-31 0001679817 2018-07-23 0001679817 OZSC:ConvertibleNotes2Member 2017-12-31 0001679817 OZSC:ConvertibleNotes3Member 2017-12-31 0001679817 OZSC:ConvertibleNotes3Member 2018-06-30 0001679817 OZSC:ConvertibleNotes4Member 2017-12-31 0001679817 OZSC:ConvertibleNotes4Member 2018-06-30 0001679817 OZSC:ConvertibleNotes1Member 2017-01-01 2017-12-31 0001679817 OZSC:ConvertibleNotes2Member 2017-01-01 2017-12-31 0001679817 OZSC:ConvertibleNotes3Member 2018-01-01 2018-06-30 0001679817 OZSC:ConvertibleNotes4Member 2018-01-01 2018-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure OZOP SURGICAL CORP. 0001679817 10-Q 2018-06-30 false --12-31 No No Yes Smaller Reporting Company Q2 2018 26297500

628235

128963

245535

52206

55082

18171

275412

110792

117348

63440

1260498

271981

489151

137283

141695

5829

1323

2641574

1527443

659895

250000

662805

430000

213018

735500

404379

220012

80989

46631

63899

208905

158381

50586

15000

451477

141931

-1381076

-1255462

3435

2859

7600

-2429023

-1562476

1024633

291155

1181

26298

13000

1260498

271981

0.001

10000000

290000000

26297500

13000000

26297500

13000000

1180768

48862

42136

14748

17901

68828

63628

29145

38870

117690

105764

43893

56771

508794

271312

228750

552232

498229

271312

186894

467995

10565

41856

84237

-459932

-229176

-214002

-534331

-406615

-378068

-8869

-13719

300280

255469

962364

933817

8869

13719

-866547

-607244

-222871

-548050

-865971

-607572

-202826

-547953

576

-328

20045

-0.04

-0.02

-0.05

22692528

25918389

13000000

10400000

-310746

-302060

183717

248288

49612

-4414

-6911

-56

-41511

16334

9500 1875

4847

297

895962

16639

-1944

4941

1944

21580

458154

250000

41846

250000

200000

400000

50000

350000

573

164620

-53908

56323

7619

150000

589176

122175

250000

2798

532289

62464

19054

53990

253510

8359

1907

250000

239151

20574

1006

NOTE 1 - ORGANIZATION   Business   Ozop Surgical Corp. (“the Company”, “we”, “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada, for the purpose of the renting different kind of Segway and bicycles, dual wheels self-balancing electric scooter and related safety equipment. Following the acquisition of OZOP Surgical, Inc. as discussed below, we have been engaged in the business of inventing, designing, developing, manufacturing and globally distributing innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties.   Reverse Merger   On April 13, 2018, we entered into and completed a share exchange agreement (the "Share Exchange Agreement") with OZOP Surgical, Inc. (“OZOP”), the shareholders of OZOP (the “OZOP Shareholders”) and Denis Razvodovskij, the holder of 2,000,000 shares of our common stock. Pursuant to the terms of the Share Exchange Agreement, the OZOP Shareholders transferred and exchanged 100% of the capital stock of OZOP in exchange for an aggregate of 25,000,000 newly issued shares of our common stock (the “Share Exchange”). After giving effect to the redemption of 2,000,000 shares of our common stock pursuant to the Redemption Agreement discussed below and the issuance of 25,000,000 shares of our common stock pursuant to the Share Exchange Agreement, we had 25,797,500 shares of common stock issued and outstanding, with the OZOP Shareholders, as a group, owning 96.9% of such shares. Our executive officers and directors, as a group, own 19,900,000 of our shares representing 77.1% of our issued and outstanding shares of common stock. The merger was accounted for as a reverse merger, whereby OZOP was considered the accounting acquirer and became a wholly-owned subsidiary of the Company. In accordance with the accounting treatment for a “reverse merger” or a “reverse acquisition,” the Company’s historical financial statements prior to the reverse merger will be replaced with the historical financial statements of OZOP prior to the reverse merger, in all future filings with the U.S. Securities and Exchange Commission (the “SEC”).   In connection with the acquisition of OZOP, we purchased and redeemed 2,000,000 shares of our common stock from Mr. Razvodovskij for a total purchase price of $350,000 pursuant to a Share Redemption Agreement (the “Redemption Agreement”). Pursuant to the terms of the Share Exchange Agreement, effective April 13, 2018, Mr. Razvodovskij resigned as the Company's Chief Executive Officer, Chief Financial Officer, Secretary, and sole director, and Michael Chermak, Salman J. Chaudhry and Eric Siu were named as directors of the Company.   On May 8, 2018, we amended our Articles of Incorporation (the “Amendment”) to change our name from Newmarkt Corp. to Ozop Surgical Corp. in order to reflect more accurately the name of our core service offering and operations. The Amendment also increased our authorized shares of capital stock to 300,000,000, of which 290,000,000 has been designated as common stock, par value $0.001, and 10,000,000 shares have been designated as preferred stock, par value $0.001 (the “Preferred Stock”). The Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time.   OZOP   OZOP was originally incorporated in Switzerland on November 28, 1998 under the name Perma Consultants Holding AG (“Perma”). On July 19, 2016, Mr. Eric Siu (“Siu”), one of our directors purchased 100% of the outstanding capital stock of Perma and changed the name from Perma to Ozop Surgical AG (“Ozop AG”). On February 1, 2018, Ozop AG was re-domiciled as a Delaware corporation and changed its name to Ozop Surgical, Inc. On July 28, 2016, Ozop formed as the sole member, Ozop Surgical, LLC (“Ozop LLC”), a Wyoming limited liability company. On October 28, 2016, Ozop acquired 100% of Ozop Surgical Limited (“Ozop HK”), from Siu, the sole shareholder of Ozop HK. Ozop HK, a private limited Company incorporated in Hong Kong.   On February 16, 2018, the Company acquired the 100% membership interest (the “Membership Interest”) in Spinus, LLC, a Texas limited liability company (“Spinus”), from RWO Medical Consulting LLC (“RWO”), a Texas limited liability company (the “Acquisition”). The Company purchased the Membership Interest from RWO in exchange for; (i) 5,000,000 shares OZOP’s common stock and ii) the assumption of all liabilities of Spinus, including an obligation of $250,000 pursuant to a license agreement by and between Spinus and a third party (the “Assumed Debt”). The Assumed Debt is secured by Spinus’s assets and is due the earlier of (i) February 16, 2019 or (ii) 15 days subsequent to the Company completing a minimum of a $3,000,000 equity raise. The Company acquired Spinus to gain control of a license rights agreement for exclusive rights to intellectual property related to minimally invasive spine surgery techniques.   The following table summarizes the preliminary value of the consideration issued and the preliminary purchase price allocation of the fair value of assets acquired and liabilities assumed in the acquisition:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt; text-align: center"> </td> <td colspan="3" style="font-size: 12pt; text-align: center">Purchase Price Allocation</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%"> Fair value of consideration issued</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">250,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> Liabilities assumed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">532,289</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total purchase consideration</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">782,289</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> Assets acquired</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">543,138</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Intellectual Property/Technology</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">239,151</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left">$</td><td style="border-bottom: Black 3pt double; text-align: right">782,289</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   The total purchase price of $782,289 has been allocated on a preliminary basis to the tangible and intangible assets acquired and liabilities assumed based on preliminary estimated fair values as of the completion of the Acquisition. These allocations reflect various preliminary estimates that are currently available and are subject to change upon the valuation being finalized within the measurement period. The final fair value of Spinus’s identifiable intangible assets will be determined primarily using the income approach which requires an estimate or forecast of all the expected future cash flows, either through the use of the relief-from-royalty method or the multi-period excess earnings method. The Company will record amortization expense assuming a straight-line basis over the expected life of the finite lived intangible assets, which approximates expected future cash flows.   Goodwill, if any, represents the amount by which the estimated consideration transferred exceeds the historical costs of the assets the Company acquired and the liabilities the Company assumed. The Company will not amortize the goodwill, but will instead test the goodwill for impairment at least annually and whenever events or circumstances have occurred that may indicate a possible impairment.

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt; text-align: center"> </td> <td colspan="3" style="font-size: 12pt; text-align: center">Purchase Price Allocation</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%"> Fair value of consideration issued</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">250,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> Liabilities assumed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">532,289</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total purchase consideration</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">782,289</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> Assets acquired</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">543,138</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Intellectual Property/Technology</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">239,151</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 3pt double; text-align: left">$</td><td style="border-bottom: Black 3pt double; text-align: right">782,289</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS   Basis of Presentation   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2018, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2018, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 8-K/A filed on June 29, 2018.   The unaudited condensed consolidated financial statements include the accounts of the Company and Ozop and its’ wholly owned subsidiaries Ozop LLC, Ozop HK and Spinus. Also included in the consolidation is Ozop Medical AG, a company registered in Munich, Germany (“Ozop Medical”). Officers owning approximately 86% of our common stock, own 100% of Ozop Medical. All intercompany accounts and transactions have been eliminated in consolidation.    Emerging Growth Companies   The Company qualifies as an “emerging growth company” under the 2012 JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to take advantage of the benefits of this extended transition period.   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.   Cash and Cash Equivalents   The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits   Accounts Receivable The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.   Inventory   Inventory is valued at the lower of cost or net realizable value. Cost is determined using the first in first out (FIFO) method. Provision for potentially obsolete or slow-moving inventory is made based on management analysis or inventory levels and future sales forecasts.   Property, plant and equipment   Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets. The estimated useful lives of office equipment is 3 years.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 30%">Office equipment</td> <td style="vertical-align: bottom; width: 70%"> </td></tr> </table>   The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The Company’s property consisted of the following at June 30, 2018 and December 31, 2017.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black; font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td><td style="color: Black; font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="color: Black; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">December 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; color: Black; text-align: left">Office equipment</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">6,885</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">1,944</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left; padding-bottom: 1pt">Less: Accumulated Depreciation</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(1,056</td><td style="padding-bottom: 1pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(621</td><td style="padding-bottom: 1pt; color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Property and Equipment, Net</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">5,829</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">1,323</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>   Depreciation expense was $273 and $435 for the three and six months ended June 30, 2018, and $162 and $297 for the three and six months ended June 30, 2017.   Patents   Intangible assets primarily represent legal costs and filings associated with obtaining patents on the Company’s new discoveries. The Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life using the straight-line method. The Company tests intangible assets with finite lives upon significant changes in the Company’s business environment and any resulting impairment charges are recorded at that time. When the Company acquires patents from related parties, the patents are recorded at the historical cost when available or the estimated legal and filing costs.   Revenue Recognition   Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the three and six months ended June 30, 2018 and 2017.   Advertising and Marketing Expenses   The Company expenses advertising and marketing costs as incurred. For the six months ended June 30, 2018, the Company recorded $35,355 of advertising and marketing expenses, and $954 for the six months ended June 30, 2017.    Research and Development   Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the six months ended June 30, 2018, the Company recorded $10,565 of research and development expenses and $41,856 and $84,237 for the three and six months ended June 30, 2017, respectively.    Fair Value of Financial Instruments   The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.    The following are the hierarchical levels of inputs to measure fair value:    <table cellspacing="3" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 48px; padding: 0.75pt"> </td> <td style="vertical-align: top; width: 47px; padding: 0.75pt">•</td> <td style="padding: 0.75pt">Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.</td></tr> <tr> <td style="vertical-align: top; padding: 0.75pt"> </td> <td style="vertical-align: top; padding: 0.75pt">•</td> <td style="padding: 0.75pt; text-align: justify">Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> <tr> <td style="vertical-align: top; padding: 0.75pt"> </td> <td style="vertical-align: top; padding: 0.75pt">•</td> <td style="padding: 0.75pt; text-align: justify">Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</td></tr> </table>   The carrying amounts of the Company's financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.    The following table represents the Company’s financial instruments that are measured at fair value on a recurring basis as of June 30, 2018, for each fair value hierarchy level:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: justify; border-bottom: Black 1pt solid">June 30, 2018</td><td style="color: Black; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; text-align: center; border-bottom: Black 1pt solid">Derivative Liabilities</td><td style="color: Black; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; text-align: center; border-bottom: Black 1pt solid">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: justify; padding-left: 0pt">Level I</td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: justify; padding-left: 0pt">Level II</td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; color: Black; text-align: justify; padding-left: 0pt">Level III</td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 25%; color: Black; text-align: right">659,895</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">659,895</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> </table>   Income Taxes    Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.   Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.   Foreign Currency Translation    The accounts of the Company's Hong Kong subsidiary are maintained in Hong Kong dollars and the accounts of the U.S. companies are maintained in USD. The accounts of the Hong Kong subsidiary were translated into USD in accordance with Accounting Standards Codification ("ASC") Topic 830, Foreign Currency Matters. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders' equity is translated at historical rates and statement of comprehensive income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, Comprehensive Income. Gains and losses resulting from the foreign currency transactions are reflected in the statements of comprehensive income.   Relevant exchange rates used in the preparation of the unaudited condensed financial statements are as follows for the periods ended June 30, 2018 and December 31, 2017 (Hong Kong dollar per one U.S. dollar):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">June 30, 2018</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">December 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Balance sheet date</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">0.1275</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">0.128</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Average rate for unaudited condensed statements of operations and comprehensive loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.1276</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.1283</td><td style="text-align: left"> </td></tr> </table>   Earnings (Loss) Per Share   The Company computes net loss per share in accordance with FASB ASC 260, “Earnings per Share.” ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period including stock options, using the treasury stock method, and convertible notes and stock warrants, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options, warrants and conversion of convertible notes. Diluted EPS excludes all dilutive potential common shares if their effect is anti-dilutive.   Recent Accounting Pronouncements   In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)”. Under this guidance, an entity is required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard will have on our consolidated financial statements.   In January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805) Clarifying the Definition of a Business” (“ASU 2017-01”). The Amendments in this Update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting, including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those periods. Early adoption of this standard is permitted. The Company adopted ASU 2017-01 on January 1, 2018, with no significant impact on the condensed consolidated financial statements.    With the exception of the new standard discussed above, there have been no other recent accounting pronouncements or changes in accounting pronouncements during the six months ended June 30, 2018, that are of significance or potential significance to the Company.

Basis of Presentation   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2018, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2018, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 8-K/A filed on June 29, 2018.   The unaudited condensed consolidated financial statements include the accounts of the Company and Ozop and its’ wholly owned subsidiaries Ozop LLC, Ozop HK and Spinus. Also included in the consolidation is Ozop Medical AG, a company registered in Munich, Germany (“Ozop Medical”). Officers owning approximately 86% of our common stock, own 100% of Ozop Medical. All intercompany accounts and transactions have been eliminated in consolidation.

Emerging Growth Companies   The Company qualifies as an “emerging growth company” under the 2012 JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to take advantage of the benefits of this extended transition period.

Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

Cash and Cash Equivalents   The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits

Accounts Receivable The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.

Inventory   Inventory is valued at the lower of cost or net realizable value. Cost is determined using the first in first out (FIFO) method. Provision for potentially obsolete or slow-moving inventory is made based on management analysis or inventory levels and future sales forecasts.

Property, plant and equipment   Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets. The estimated useful lives of office equipment is 3 years.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 30%">Office equipment</td> <td style="vertical-align: bottom; width: 70%"> </td></tr> </table>   The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The Company’s property consisted of the following at June 30, 2018 and December 31, 2017.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black; font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td><td style="color: Black; font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="color: Black; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">December 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; color: Black; text-align: left">Office equipment</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">6,885</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">1,944</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left; padding-bottom: 1pt">Less: Accumulated Depreciation</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(1,056</td><td style="padding-bottom: 1pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(621</td><td style="padding-bottom: 1pt; color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Property and Equipment, Net</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">5,829</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">1,323</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>   Depreciation expense was $273 and $435 for the three and six months ended June 30, 2018, and $162 and $297 for the three and six months ended June 30, 2017.

Patents   Intangible assets primarily represent legal costs and filings associated with obtaining patents on the Company’s new discoveries. The Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life using the straight-line method. The Company tests intangible assets with finite lives upon significant changes in the Company’s business environment and any resulting impairment charges are recorded at that time. When the Company acquires patents from related parties, the patents are recorded at the historical cost when available or the estimated legal and filing costs.

Revenue Recognition   Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the three and six months ended June 30, 2018 and 2017.

Advertising and Marketing Expenses   The Company expenses advertising and marketing costs as incurred. For the six months ended June 30, 2018, the Company recorded $35,355 of advertising and marketing expenses, and $954 for the six months ended June 30, 2017.

Research and Development   Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the six months ended June 30, 2018, the Company recorded $10,565 of research and development expenses and $41,856 and $84,237 for the three and six months ended June 30, 2017, respectively.

Fair Value of Financial Instruments   The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.    The following are the hierarchical levels of inputs to measure fair value:    <table cellspacing="3" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 48px; padding: 0.75pt"> </td> <td style="vertical-align: top; width: 47px; padding: 0.75pt">•</td> <td style="padding: 0.75pt">Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.</td></tr> <tr> <td style="vertical-align: top; padding: 0.75pt"> </td> <td style="vertical-align: top; padding: 0.75pt">•</td> <td style="padding: 0.75pt; text-align: justify">Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> <tr> <td style="vertical-align: top; padding: 0.75pt"> </td> <td style="vertical-align: top; padding: 0.75pt">•</td> <td style="padding: 0.75pt; text-align: justify">Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</td></tr> </table>   The carrying amounts of the Company's financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.    The following table represents the Company’s financial instruments that are measured at fair value on a recurring basis as of June 30, 2018, for each fair value hierarchy level:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: justify; border-bottom: Black 1pt solid">June 30, 2018</td><td style="color: Black; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; text-align: center; border-bottom: Black 1pt solid">Derivative Liabilities</td><td style="color: Black; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; text-align: center; border-bottom: Black 1pt solid">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: justify; padding-left: 0pt">Level I</td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: justify; padding-left: 0pt">Level II</td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; color: Black; text-align: justify; padding-left: 0pt">Level III</td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 25%; color: Black; text-align: right">659,895</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">659,895</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> </table>

Income Taxes    Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.   Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.

Foreign Currency Translation    The accounts of the Company's Hong Kong subsidiary are maintained in Hong Kong dollars and the accounts of the U.S. companies are maintained in USD. The accounts of the Hong Kong subsidiary were translated into USD in accordance with Accounting Standards Codification ("ASC") Topic 830, Foreign Currency Matters. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders' equity is translated at historical rates and statement of comprehensive income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, Comprehensive Income. Gains and losses resulting from the foreign currency transactions are reflected in the statements of comprehensive income.   Relevant exchange rates used in the preparation of the unaudited condensed financial statements are as follows for the periods ended June 30, 2018 and December 31, 2017 (Hong Kong dollar per one U.S. dollar):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">June 30, 2018</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">December 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Balance sheet date</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">0.1275</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">0.128</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Average rate for unaudited condensed statements of operations and comprehensive loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.1276</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.1283</td><td style="text-align: left"> </td></tr> </table>

Earnings (Loss) Per Share   The Company computes net loss per share in accordance with FASB ASC 260, “Earnings per Share.” ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period including stock options, using the treasury stock method, and convertible notes and stock warrants, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options, warrants and conversion of convertible notes. Diluted EPS excludes all dilutive potential common shares if their effect is anti-dilutive.

Recent Accounting Pronouncements   In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)”. Under this guidance, an entity is required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard will have on our consolidated financial statements.   In January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805) Clarifying the Definition of a Business” (“ASU 2017-01”). The Amendments in this Update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting, including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those periods. Early adoption of this standard is permitted. The Company adopted ASU 2017-01 on January 1, 2018, with no significant impact on the condensed consolidated financial statements.    With the exception of the new standard discussed above, there have been no other recent accounting pronouncements or changes in accounting pronouncements during the six months ended June 30, 2018, that are of significance or potential significance to the Company.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: justify; border-bottom: Black 1pt solid">June 30, 2018</td><td style="color: Black; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; text-align: center; border-bottom: Black 1pt solid">Derivative Liabilities</td><td style="color: Black; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; text-align: center; border-bottom: Black 1pt solid">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: justify; padding-left: 0pt">Level I</td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: justify; padding-left: 0pt">Level II</td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">—  </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; color: Black; text-align: justify; padding-left: 0pt">Level III</td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 25%; color: Black; text-align: right">659,895</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">659,895</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">June 30, 2018</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">December 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Balance sheet date</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">0.1275</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">0.128</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Average rate for unaudited condensed statements of operations and comprehensive loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.1276</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.1283</td><td style="text-align: left"> </td></tr> </table>

NOTE 3 – INTANGIBLE ASSETS   Patents as of June 30, 2018 consist of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; color: Black; text-align: left; padding-left: 5.4pt">Patents and trademarks</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">138,934</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left; padding-left: 5.4pt">License rights</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">500,000</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated amortization</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(12,500</td><td style="padding-bottom: 1pt; color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net carrying amount</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">626,434</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>   Amortization expense for the three and six months ended June 30, 2018 was $2,206 and $4,412, respectively.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; color: Black; text-align: left; padding-left: 5.4pt">Patents and trademarks</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">138,934</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left; padding-left: 5.4pt">License rights</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">500,000</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated amortization</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(12,500</td><td style="padding-bottom: 1pt; color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net carrying amount</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">626,434</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

NOTE 4 - CONVERTIBLE NOTES PAYABLE   During the year ended December 31, 2017, OZOP issued 19 convertible promissory notes (the “2017 Notes”), in amounts of $10,000 to $50,000. OZOP received proceeds of $710,000 in the aggregate. The 2017 Notes mature(d) on their one- year anniversary and bear interest at ten percent (10%). The holders can convert the notes and any unpaid interest due, into shares of the Company’s common stock on the 15th business day that the Company becomes listed, at conversion prices equal to discounts of 35%-50% of the average of the three lowest closing prices of the common stock. OZOP also issued $25,500 of convertible notes for consulting fees. During the six months ended June 30, 2018, the Company issued a $50,000 convertible promissory note (the “March 2018 Note”) and received proceeds of $50,000. The Company determined that the conversion feature of the 2017 Notes and the March 2018 Note (together, the “Notes”) did not meet the criteria of an embedded derivative and therefore the conversion feature was not bi-furcated and accounted for as a derivative because the Company was a private company, there was no quoted price and no active market for the Company’s common stock. The Company became a public company on April 13, 2018, and on that date the Company determined the conversion feature of the Notes represented an embedded derivative since the Notes were convertible into a variable number of shares upon conversion. Accordingly, on April 13, 2018, the Notes were not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability. Accordingly, the fair value of the derivative instruments of the Notes that occurred prior to April 13, 2018, were recorded as a liability on April 13, 2018, on the unaudited condensed consolidated balance sheet with the corresponding amount recorded as a discount to the Note. Such discount is being amortized from the date of issuance to the maturity dates of the Notes. The change in the fair value of the liability for derivative contracts are recorded in other income or expenses in the unaudited condensed consolidated statements of operations at the end of each quarter, with the offset to the derivative liability on the balance sheet. The embedded feature included in the Notes resulted in an initial debt discount of $620,075, interest expense of $14,000 and initial derivative liability of $634,075. For the six months ended June 30, 2018, amortization of the debt discounts of $398,886 was charged to interest expense. During the six months ended June 30, 2018, investors converted $570,500 of principal and $19,857 of accrued interest into 1,180,768 shares of common stock. Due to the conversions prior to the maturity of the converted notes, the Company recorded additional interest expense and a loss on extinguishment of debt of $234,386. As of June 30, 2018, the outstanding principal balance of the 2017 Notes was $215,000 with a carrying value as of June 30, 2018, of $196,750, net of unamortized discounts of $18,250. The March 2018 Note was part of the above conversions, and the balance of the March 2018 Note as of June 30, 2018 is $-0-.   On April 13, 2018, we issued a convertible promissory note in the principal amount of $442,175 (the “Note”), pursuant to a Securities Purchase Agreement we entered into with an investor dated April 1, 2018. The Note bears interest at the rate of 12% per annum and is due and payable on April 13, 2019. The note is convertible at any time following the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 55% of the average of the lowest trading price for the 25 days prior to conversion. The note was funded on April 13, 2018, when the Company received proceeds of $350,000, after OID of $57,675, and disbursements for the lender’s transaction costs, fees and expenses of $34,500, of which $25,000 were recorded as discounts against the debt to be amortized into interest expense through maturity. Periodic payments are due by us on the Note at the rate of $850 per day (the “Repayment Amount”) via direct withdrawal from our bank account, beginning on April 27, 2018 and to last for a 30-day period. Following this period, the Repayment Amount increased to $1,100 per day until the Note is satisfied in full. On June 28, 2018, the Note was amended to increase the Repayment Amount to $1,750 per day. During the six months ended June 30, 2018, principal payments of $41,800 were made. The embedded conversion feature included in the note resulted in an initial debt discount of $407,675 interest expense of $408,280 and an initial derivative liability of $815,955. For the six months ended June 30, 2018, amortization of the debt discounts of $106,243 was charged to interest expense. As of June 30, 2018, the outstanding principal balance of the note was $400,375 with a carrying value as of June 30, 2018, of $16,268, net of unamortized discounts of $384,107.   We may prepay in full the unpaid principal and interest on the Note, with at least 20 trading days’ notice, (a) any time prior to the 180th day after the issuance date, by paying 130% of the principal amount of the Note together with accrued interest thereon; and (b) any time beginning on the 181st day after the issuance date and ending on the 364th day after the issuance date, by paying 150% of the principal amount of the Note together with accrued interest thereon. After the expiration of the 364th day after the issuance date, we have no right of prepayment.   In connection with our obligations under the Note, our executive officers and the Company entered into a Pledge Agreement (the “Pledge Agreement”) whereby they pledged as collateral for the Loan an aggregate of 19,900,000 shares of our common stock and we pledged the shares of our subsidiary OZOP Surgical, Inc. (collectively, the “Collateral”). Upon a default under the terms of the Note, Carebourn may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease or dispose of the Collateral.   A summary of the convertible note balance as of June 30, 2018 and December 31, 2017 is as follows   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black"> </td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; color: Black; text-align: left">Principal balance</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">615,375</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">735,500</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left; padding-bottom: 1pt">Unamortized discount</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(402,357</td><td style="padding-bottom: 1pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">-0-</td><td style="padding-bottom: 1pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; padding-bottom: 2.5pt">Ending balance, net</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">213,018</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">735,500</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

NOTE 5 – DERIVATIVE LIABILITIES     The Company became a public company on April 13, 2018, and on that date the Company determined the conversion feature of the Notes represented an embedded derivative since the Notes were convertible into a variable number of shares upon conversion. Accordingly, on April 13, 2018, the Notes were not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability.   The Company valued the derivative liabilities at June 30, 2018, and April 13, 2018, at $659,895 and $1,450,030, respectively. The Company used the Monte Carlo simulation valuation model with the following assumptions as of June 30, 2018; risk-free interest rates from 2.06% to 2.24% and volatility of 121% to 164%, and the following assumptions at April 13, 2018, risk-free interest rates from 1.06% to 1.28% and volatility of 140% to 260%. The initial derivative liabilities for convertible notes issued during the six months ended June 30, 2018, used the following assumptions; risk-free interest rates from 1.89% to 2.29% and volatility of 120% to 331%.   A summary of the activity related to derivative liabilities for the six months ended June 30, 2018, is as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; color: Black; text-align: left">Beginning balance</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">-0-</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Issued during period</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">1,450,030</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Converted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">(534,666</td><td style="color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left; padding-bottom: 1pt">Change in fair value recognized in operations</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(255,469</td><td style="padding-bottom: 1pt; color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; padding-bottom: 2.5pt">Ending balance</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">659,895</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; color: Black; text-align: left">Beginning balance</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">-0-</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Issued during period</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">1,450,030</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Converted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">(534,666</td><td style="color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left; padding-bottom: 1pt">Change in fair value recognized in operations</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(255,469</td><td style="padding-bottom: 1pt; color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; padding-bottom: 2.5pt">Ending balance</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">659,895</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

NOTE 6 – NOTES PAYABLE   The Company has the following note payables outstanding:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black"> </td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; color: Black; text-align: left">Note payable, interest at 8%, matures September 6, 2018</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">370,000</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Note payable, includes $10,000 original issue discount, matures October 30, 2018</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">60,000</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Note payable, interest</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">230,000</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left; padding-bottom: 1pt">Other, due on demand</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">2,805</td><td style="padding-bottom: 1pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Total notes payable</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">662,805</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>   On June 28, 2018, the Company issued a $230,000 principal amount Promissory note for a purchase price of $200,000 due on August 27, 2018 (the “June 2018 Note”). The June 2018 Note provides for standard and customary events of default such as failing to timely make payments under the June 2018 Note when due. In addition, a default under the June 2018 Note will result in a default under the April 2018 Note (see Note 5). We may prepay in full the unpaid principal on the June 2018 Note. The June 2018 Note also contains customary positive and negative covenants.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black"> </td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; color: Black; text-align: left">Note payable, interest at 8%, matures September 6, 2018</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">370,000</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Note payable, includes $10,000 original issue discount, matures October 30, 2018</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">60,000</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Note payable, interest</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">230,000</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left; padding-bottom: 1pt">Other, due on demand</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">2,805</td><td style="padding-bottom: 1pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Total notes payable</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">662,805</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

NOTE 7 – RELATED PARTY TRANSACTIONS   Management Fees and related party payables   For the three and six months ended June 30, 2018, the Company (including the Company’s subsidiaries) recorded expenses to its officers in the following amounts:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: justify"> </td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three months ended</td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six months ended</td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: justify"> </td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 42%; color: Black; text-align: justify">CEO, parent</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 25%; color: Black; text-align: right">30,000</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 25%; color: Black; text-align: right">60,000</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: justify">CEO, subsidiary</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">30,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">60,000</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: justify">COO</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">30,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">60,000</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: justify; padding-bottom: 1pt">CFO</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">30,000</td><td style="padding-bottom: 1pt; color: Black; text-align: left"> </td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">60,000</td><td style="padding-bottom: 1pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">120,000</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">240,000</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>   As of June 30, 2018, and December 31, 2017, included in accounts payable and accrued expenses, related party is $404,379 and $220,012, respectively, for the following amounts owed the Company’s officers:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: justify"> </td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; color: Black; text-align: justify">CEO, parent</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">80,989</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">46,631</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: justify">CEO, subsidiary</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">63,899</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">-0-</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: justify">COO</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">208,905</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">158,381</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: justify; padding-bottom: 1pt">CFO</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">50,586</td><td style="padding-bottom: 1pt; color: Black; text-align: left"> </td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">15,000</td><td style="padding-bottom: 1pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">404,379</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">220,012</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: justify"> </td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three months ended</td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six months ended</td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: justify"> </td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 42%; color: Black; text-align: justify">CEO, parent</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 25%; color: Black; text-align: right">30,000</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 25%; color: Black; text-align: right">60,000</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: justify">CEO, subsidiary</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">30,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">60,000</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: justify">COO</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">30,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">60,000</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: justify; padding-bottom: 1pt">CFO</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">30,000</td><td style="padding-bottom: 1pt; color: Black; text-align: left"> </td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">60,000</td><td style="padding-bottom: 1pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">120,000</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">240,000</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: justify"> </td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2018</td><td style="color: Black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="color: Black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; color: Black; text-align: justify">CEO, parent</td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">80,989</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 3%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 20%; color: Black; text-align: right">46,631</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: justify">CEO, subsidiary</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">63,899</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">-0-</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: justify">COO</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">208,905</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">158,381</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: justify; padding-bottom: 1pt">CFO</td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">50,586</td><td style="padding-bottom: 1pt; color: Black; text-align: left"> </td><td style="color: Black; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">15,000</td><td style="padding-bottom: 1pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">404,379</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="color: Black; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">220,012</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> NOTE 8 – LICENSE FEE PAYABLE   On February 1, 2018, Spinus entered into an Intellectual Property Licensing Agreement (the “Licensing Agreement”). The Company assumed the obligations under the Licensing Agreement and pledged the assets of Spinus as security. Pursuant to the terms of the Licensing Agreement, in consideration of $250,000 Spinus has the exclusive rights to certain patents and the non-exclusive rights to other patents. The patents surround mechanical or inflatable expandable interbody implant products. The $250,000 is due the earlier of (i) February 16, 2019 or (ii) 15 days subsequent to the Company completing a minimum of a $3,000,000 equity raise. The Company also will pay a royalty of 7% of net sales on any product sold utilizing any of the patents.

NOTE 9 – STOCKHOLDERS’ EQUITY   Common stock   On April 13, 2018, the Company completed the reverse merger with Newmarkt (see Note 1) and issued 2,797,500 shares of common stock. Also on April 13, 2018, the Company purchased and redeemed 2,000,000 shares of common stock for a purchase price of $350,000 pursuant to the Redemption Agreement.   During the six months ended June 30, 2018, we sold 500,000 shares of our common stock at a price of $0.50 per share to seven investors and received proceeds of $250,000.   During the six months ended June 30, 2018, holders of an aggregate of $590,357 in principal and accrued interest of convertible debt issued by OZOP converted their debt and accrued interest into 1,180,768 shares of our common stock at a conversion price of $0.50 per share. These shares have not been certificated and are included in common stock to be issued on the June 30, 2018, balance sheet presented herein.   As of June 30, 2018, the Company has 290,000,000 shares of $0.001 par value common stock authorized and there are 26,297,500 shares of common stock issued and outstanding and 1,180,768 shares of common stock to be issued.   Preferred stock   As of June 30, 2018, 10,000,000 shares have been authorized as preferred stock, par value $0.001 (the “Preferred Stock”), which such Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time. As of June 30, 2018, there are no shares of preferred stock issued and outstanding.   Stock subscription receivable   The Company recorded a stock subscription receivable from its’ officers and directors of $7,600 related to the issuance of 7,600,000 shares of common stock.

NOTE 10 – GOING CONCERN AND MANAGEMENT’S PLANS   The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. At June 30, 2018, the Company had a stockholders’ deficit of $1,381,076 and a working capital deficit of $2,013,339. In addition, the Company has generated losses since inception. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern.   Management’s Plans   In April 2018, OZOP entered into and completed a share exchange agreement with Newmarkt Corp., a Nevada corporation (see Note 1), a publicly traded company. As a public company, management believes it will be able to access the public equities market for fund raising for product development and regulatory approvals, sales and marketing and as we expand our distribution in the US market, we will need to meet increasing inventory requirements.   On June 11, 2018, the Company entered into an engagement letter with an Underwriter, with respect to the sale of shares of our preferred stock and warrants to purchase our common stock. Under the terms and subject to the conditions contained in the engagement letter, we have agreed to issue and sell to certain investors through the Underwriter, and the Underwriter has agreed to offer and sell, a minimum of 750,000 and up to 5,000,000 Units, at $2.00 per unit on a best efforts basis. Each Unit consists of one (1) share of Series A 6% Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) and one (1) Common Stock Purchase Warrant (the “Warrants”). Each share of Series A Preferred Stock is entitled to dividends at the rate of 6% per annum, accrued quarterly, is redeemable by the holders three (3) years after issuance and converts into shares of our Common Stock at a rate of $1.00 per share at the option of the holder. Each Warrant entitles the holder to purchase our Common Stock at an exercise price of $1.50 per share for a period of five (5) years after their issuance.

NOTE 11 – SUBSEQUENT EVENTS   On July 23, 2018, the Company, through its wholly owned subsidiary, OZOP (Guangdong) Medical Technology Co., Ltd., a wholly owned foreign enterprise in China, acquired a 100% ownership interest in Yijingtong (Beijing) Technology Development Ltd (“Yijingtong”) from its shareholders who are unrelated parties pursuant to the terms of an Equity Transfer Agreement dated July 23, 2018 (the “Equity Transfer Agreement”). Yijington is a China based distributor of minimally invasive surgical (MIS) products to the orthopedic and neurosurgical markets in China.   Pursuant to the terms of the Equity Transfer Agreement, we agreed to pay the sellers of the Yijingtong equity interest RMB 1,000,000 (approximately US$147,815) payable in cash within 120 days of closing, in addition to inventory valued at RMB 4,072,719 (approximately US$ 602,009), which the parties will separately agree to payment and delivery terms. The sellers of Yijingtong will begin the registration change process upon execution of the Equity Transfer Agreement. In the event either party breaches the agreement, the non-breaching party shall have the right to request termination of the agreement and claim compensation from the breaching party for all economic losses.

250000

532289

782289

543138

239151

782289

2000000

350000

1.00

5000000 250000

6885

1944

1056

621

.1275

.128

.1276

.1283

435

273

162

297

35355

954

138934 500000 -12500 626434

4412

2206

615375

735500

402357

659895

1450030 -534666

-255469

0.0189

0.0206

0.0106

0.0229

0.0224

0.0128

1.20

1.21

1.40

3.31

1.64

2.60

370000

60000

230000

2805

662805

240000

120000

30000

60000

30000

60000

30000

60000

30000

60000

500000

.50

250000

590357

1180768

.50

2013339

147815 602009

710000

50000

350000

50000 442175 620075 407675 14000 408280 634075 815955 398886 106243 570500 19857 1180768 215000 400375 196750 16268 18250 384107 57675

41800

EX-101.SCH 7 ozsc-20180630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statement of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - LICENSE FEE PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - GOING CONCERN AND MANAGEMENT'S PLANS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - ORGANIZATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - DERIVATIVE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - ORGANIZATION - Purchase price allocation of acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - ORGANIZATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Property and equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Financial instruments that are measured at fair value on a recurring basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Relevant exchange rates used (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - INTANGIBLE ASSETS - Patents (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - CONVERTIBLE NOTES PAYABLE - Summary of convertible note balance (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - DERIVATIVE LIABILITIES - Summary of activity related to derivative liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - NOTES PAYABLE - Note payables outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - RELATED PARTY TRANSACTIONS - Expenses to officers (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - RELATED PARTY TRANSACTIONS - Amounts owed to officers, included in accounts payable and accrued expenses, related party (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - LICENSE FEE PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - GOING CONCERN AND MANAGEMENT'S PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ozsc-20180630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 ozsc-20180630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 ozsc-20180630_lab.xml XBRL LABEL FILE Business Acquisition [Axis] Acquisition of Spinus, LLC Acquisition of Newmarkt Fair Value Hierarchy and NAV [Axis] Level I Level II Level III Currency [Axis] Balance sheet date Average rate for unaudited condensed statements of operations and comprehensive loss Related Party [Axis] CEO, parent CEO, subsidiary COO CFO Debt Instrument [Axis] March 2018 Note Notes Note Issued Pursuant to Securities Purchase Agreement 2017 Notes Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Prepaid expenses Accounts receivable Inventory Total Current Assets Office equipment, net Patents and trademarks, net License Rights TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities Current Liabilities Accounts payable and accrued expenses Accounts payable and accrued expenses, related parties Convertible notes payable, net of discounts Notes Payable License fee payable Derivative liabilities Total Current Liabilities Stockholders' Deficit Preferred stock (10,000,000 shares authorized, par value $0.001, no shares issued and outstanding) Common stock (290,000,000 shares authorized par value $0.001 26,297,500 and 13,000,000 shares issued and outstanding June 30, 2018 and December 31, 2017, respectively) Common stock to be issued (1,180,768 shares issuable June 30, 2018) Additional paid in capital Accumulated Deficit Stock subscription receivable Accumulated comprehensive income Total Stockholders' Deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Common stock to be issued, shares Income Statement [Abstract] Revenue Cost of Goods Gross Profit Operating expenses: Research and development General and administrative Total operating expenses Operating loss Other (income) expenses: Interest expense Gain on change in fair value of derivatives Gain on extinguishment of debt Total Other Expenses (Income) Net Loss Other comprehensive income (loss): Foreign currency translation adjustment Comprehensive loss Loss per share Weighted average shares outstanding - Basic and dilut Statement [Table] Statement [Line Items] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operations Non-cash interest expense Amortization and depreciation Gain on fair value change of derivatives Gain on extinguishment of debt Issuance of convertible notes for fees Changes in operating assets and liabilities: Inventory Accounts receivable Prepaid expenses Accounts payable and accrued expenses Accounts payable and accrued expenses, related parties Net cash used in operating activities Cash flows from investing activities: Cash acquired in acquisitions Purchase of office and computer equipment Net cash provided by (used in) investing activities Cash flows from financing activities: Redemption of common shares Proceeds from issuances of convertible notes payable Proceeds from issuances of notes payable Proceeds from sale of common stock Payments of principal of convertible note payable and notes payable Net cash provided by financing activities Effects of exchange rate on cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, Beginning of period Cash and cash equivalents, End of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income taxes Schedule of non-cash Investing or Financing Activity: Original issue discount included in notes payable Issuance of common stock upon convertible note and accrued interest conversion Issuance of common stock for contribution of intellectual property Acquisitions Issuance of Common stock as consideration Assumed liabilities Accounts receivable Paid in capital Inventory Prepaid expenses Other Assets Intangible assets Cash acquired Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS Debt Disclosure [Abstract] CONVERTIBLE NOTES PAYABLE Notes to Financial Statements DERIVATIVE LIABILITIES NOTES PAYABLE Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS LICENSE FEE PAYABLE Equity [Abstract] STOCKHOLDERS' EQUITY GOING CONCERN AND MANAGEMENT'S PLANS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Emerging Growth Companies Use of Estimates Cash and Cash Equivalents Accounts Receivable Inventory Property, plant and equipment Patents Revenue Recognition Advertising and Marketing Expenses Research and Development Fair Value of Financial Instruments Income Taxes Foreign Currency Translation Earnings (Loss) Per Share Recent Accounting Pronouncements Purchase price allocation of acquisition Property and equipment Financial instruments that are measured at fair value on a recurring basis Relevant exchange rates used Patents Summary of convertible note balance Summary of activity related to derivative liabilities Note payables outstanding Expenses to officers Amounts owed to officers, included in accounts payable and accrued expenses, related party Fair value of consideration issued Liabilities assumed Total purchase consideration EX-101.PRE 11 ozsc-20180630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Aug. 14, 2018
Document And Entity Information
Entity Registrant Name	OZOP SURGICAL CORP.
Entity Central Index Key	0001679817
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		26,297,500
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2018

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheet (Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current Assets
Cash	$ 275,412	$ 110,792
Prepaid expenses	55,082	18,171
Accounts receivable	52,206
Inventory	245,535
Total Current Assets	628,235	128,963
Office equipment, net	5,829	1,323
Patents and trademarks, net	137,283	141,695
License Rights	489,151
TOTAL ASSETS	1,260,498	271,981
Current Liabilities
Accounts payable and accrued expenses	451,477	141,931
Accounts payable and accrued expenses, related parties	404,379	220,012
Convertible notes payable, net of discounts	213,018	735,500
Notes Payable	662,805	430,000
License fee payable	250,000
Derivative liabilities	659,895
Total Current Liabilities	2,641,574	1,527,443
Stockholders' Deficit
Preferred stock (10,000,000 shares authorized, par value $0.001, no shares issued and outstanding)
Common stock (290,000,000 shares authorized par value $0.001 26,297,500 and 13,000,000 shares issued and outstanding June 30, 2018 and December 31, 2017, respectively)	26,298	13,000
Common stock to be issued (1,180,768 shares issuable June 30, 2018)	1,181
Additional paid in capital	1,024,633	291,155
Accumulated Deficit	(2,429,023)	(1,562,476)
Stock subscription receivable	(7,600)
Accumulated comprehensive income	3,435	2,859
Total Stockholders' Deficit	(1,381,076)	(1,255,462)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,260,498	$ 271,981

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheet (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	290,000,000	290,000,000
Common stock, shares issued	26,297,500	13,000,000
Common stock, shares outstanding	26,297,500	13,000,000
Common stock to be issued, shares	1,180,768

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Revenue	$ 105,764	$ 43,893	$ 117,690	$ 56,771
Cost of Goods	63,628	29,145	68,828	38,870
Gross Profit	42,136	14,748	48,862	17,901
Operating expenses:
Research and development		41,856	10,565	84,237
General and administrative	271,312	186,894	498,229	467,995
Total operating expenses	271,312	228,750	508,794	552,232
Operating loss	(229,176)	(214,002)	(459,932)	(534,331)
Other (income) expenses:
Interest expense	933,817	8,869	962,364	13,719
Gain on change in fair value of derivatives	(255,469)		(255,469)
Gain on extinguishment of debt	(300,280)		(300,280)
Total Other Expenses (Income)	378,068	8,869	406,615	13,719
Net Loss	(607,244)	(222,871)	(866,547)	(548,050)
Other comprehensive income (loss):
Foreign currency translation adjustment	(328)	20,045	576	97
Comprehensive loss	$ (607,572)	$ (202,826)	$ (865,971)	$ (547,953)
Loss per share	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.05)
Weighted average shares outstanding - Basic and dilut	25,918,389	13,000,000	22,692,528	10,400,000

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net loss	$ (866,547)	$ (548,050)
Adjustments to reconcile net loss to net cash used in operations
Non-cash interest expense	895,962
Amortization and depreciation	4,847	297
Gain on fair value change of derivatives	255,469
Gain on extinguishment of debt	300,280
Issuance of convertible notes for fees	9,500	1,875
Changes in operating assets and liabilities:
Inventory	16,334
Accounts receivable	(41,511)
Prepaid expenses	(6,911)	(56)
Accounts payable and accrued expenses	49,612	(4,414)
Accounts payable and accrued expenses, related parties	183,717	248,288
Net cash used in operating activities	(310,746)	(302,060)
Cash flows from investing activities:
Cash acquired in acquisitions	21,580
Purchase of office and computer equipment	(4,941)	(1,944)
Net cash provided by (used in) investing activities	16,639	(1,944)
Cash flows from financing activities:
Redemption of common shares	(350,000)
Proceeds from issuances of convertible notes payable	400,000	50,000
Proceeds from issuances of notes payable	200,000	200,000
Proceeds from sale of common stock	250,000
Payments of principal of convertible note payable and notes payable	(41,846)
Net cash provided by financing activities	458,154	250,000
Effects of exchange rate on cash and cash equivalents	573	96
Net increase (decrease) in cash and cash equivalents	164,620	(53,908)
Cash and cash equivalents, Beginning of period	110,792	117,348
Cash and cash equivalents, End of period	275,412	63,440
Supplemental disclosure of cash flow information:
Cash paid for interest	56,323	7,619
Cash paid for income taxes
Schedule of non-cash Investing or Financing Activity:
Original issue discount included in notes payable	122,175
Issuance of common stock upon convertible note and accrued interest conversion	589,176
Issuance of common stock for contribution of intellectual property		$ 150,000
Acquisition of Spinus, LLC
Acquisitions
Issuance of Common stock as consideration	250,000
Assumed liabilities	532,289
Accounts receivable	(19,054)
Inventory	(253,510)
Other Assets	(250,000)
Intangible assets	(239,151)
Cash acquired	20,574
Acquisition of Newmarkt
Acquisitions
Issuance of Common stock as consideration	2,798
Assumed liabilities	62,464
Paid in capital	(53,990)
Inventory	(8,359)
Prepaid expenses	(1,907)
Intangible assets
Cash acquired	$ 1,006

XML 17 R6.htm IDEA: XBRL DOCUMENT

ORGANIZATION

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION

NOTE 1 - ORGANIZATION

Business

Reverse Merger

OZOP

	Purchase Price Allocation
Fair value of consideration issued	$	250,000
Liabilities assumed		532,289
Total purchase consideration	$	782,289
Assets acquired	$	543,138
Intellectual Property/Technology		239,151
	$	782,289

XML 18 R7.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

Basis of Presentation

Emerging Growth Companies

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventory

Property, plant and equipment

Office equipment

	June 30, 2018			December 31, 2017
Office equipment	$	6,885		$	1,944
Less: Accumulated Depreciation		(1,056	)		(621	)
Property and Equipment, Net	$	5,829		$	1,323

Depreciation expense was $273 and $435 for the three and six months ended June 30, 2018, and $162 and $297 for the three and six months ended June 30, 2017.

Patents

Revenue Recognition

Advertising and Marketing Expenses

Research and Development

Fair Value of Financial Instruments

The following are the hierarchical levels of inputs to measure fair value:

	•	Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
	•	Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	•	Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

The following table represents the Company’s financial instruments that are measured at fair value on a recurring basis as of June 30, 2018, for each fair value hierarchy level:

June 30, 2018	Derivative Liabilities		Total
Level I	$	—	$	—
Level II	$	—	$	—
Level III	$	659,895	$	659,895

Income Taxes

Foreign Currency Translation

June 30,

2018

December 31,

2017

Balance sheet date

0.1275

0.128

Average rate for unaudited condensed statements of operations and comprehensive loss

0.1276

0.1283

Earnings (Loss) Per Share

Recent Accounting Pronouncements

XML 19 R8.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 3 – INTANGIBLE ASSETS

Patents as of June 30, 2018 consist of the following:

Patents and trademarks	$	138,934
License rights		500,000
Accumulated amortization		(12,500	)
Net carrying amount	$	626,434

Amortization expense for the three and six months ended June 30, 2018 was $2,206 and $4,412, respectively.

XML 20 R9.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

CONVERTIBLE NOTES PAYABLE

NOTE 4 - CONVERTIBLE NOTES PAYABLE

A summary of the convertible note balance as of June 30, 2018 and December 31, 2017 is as follows

	June 30, 2018			December 31, 2017
Principal balance	$	615,375		$	735,500
Unamortized discount		(402,357	)		-0-
Ending balance, net		213,018		$	735,500

XML 21 R10.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

DERIVATIVE LIABILITIES

NOTE 5 – DERIVATIVE LIABILITIES

A summary of the activity related to derivative liabilities for the six months ended June 30, 2018, is as follows:

Beginning balance	$	-0-
Issued during period		1,450,030
Converted		(534,666	)
Change in fair value recognized in operations		(255,469	)
Ending balance	$	659,895

XML 22 R11.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

NOTES PAYABLE

NOTE 6 – NOTES PAYABLE

The Company has the following note payables outstanding:

	June 30, 2018
Note payable, interest at 8%, matures September 6, 2018	$	370,000
Note payable, includes $10,000 original issue discount, matures October 30, 2018		60,000
Note payable, interest		230,000
Other, due on demand		2,805
Total notes payable	$	662,805

XML 23 R12.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

6 Months Ended

Jun. 30, 2018

RELATED PARTY TRANSACTIONS

NOTE 7 – RELATED PARTY TRANSACTIONS

Management Fees and related party payables

For the three and six months ended June 30, 2018, the Company (including the Company’s subsidiaries) recorded expenses to its officers in the following amounts:

	Three months ended		Six months ended
	June 30, 2018		June 30, 2018
CEO, parent	$	30,000	$	60,000
CEO, subsidiary		30,000		60,000
COO		30,000		60,000
CFO		30,000		60,000
Total	$	120,000	$	240,000

	June 30, 2018		December 31, 2017
CEO, parent	$	80,989	$	46,631
CEO, subsidiary		63,899		-0-
COO		208,905		158,381
CFO		50,586		15,000
Total	$	404,379	$	220,012

XML 24 R13.htm IDEA: XBRL DOCUMENT

LICENSE FEE PAYABLE

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

LICENSE FEE PAYABLE

NOTE 8 – LICENSE FEE PAYABLE

XML 25 R14.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 9 – STOCKHOLDERS’ EQUITY

Common stock

During the six months ended June 30, 2018, we sold 500,000 shares of our common stock at a price of $0.50 per share to seven investors and received proceeds of $250,000.

Preferred stock

Stock subscription receivable

The Company recorded a stock subscription receivable from its’ officers and directors of $7,600 related to the issuance of 7,600,000 shares of common stock.

XML 26 R15.htm IDEA: XBRL DOCUMENT

GOING CONCERN AND MANAGEMENT'S PLANS

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN AND MANAGEMENT'S PLANS

NOTE 10 – GOING CONCERN AND MANAGEMENT’S PLANS

Management’s Plans

XML 27 R16.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 11 – SUBSEQUENT EVENTS

XML 28 R17.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Emerging Growth Companies

Emerging Growth Companies

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Accounts Receivable

Accounts Receivable

Inventory

Inventory

Property, plant and equipment

Property, plant and equipment

Office equipment

	June 30, 2018			December 31, 2017
Office equipment	$	6,885		$	1,944
Less: Accumulated Depreciation		(1,056	)		(621	)
Property and Equipment, Net	$	5,829		$	1,323

Depreciation expense was $273 and $435 for the three and six months ended June 30, 2018, and $162 and $297 for the three and six months ended June 30, 2017.

Patents

Patents

Revenue Recognition

Revenue Recognition

Advertising and Marketing Expenses

Advertising and Marketing Expenses

Research and Development

Research and Development

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The following are the hierarchical levels of inputs to measure fair value:

	•	Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
	•	Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	•	Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

The following table represents the Company’s financial instruments that are measured at fair value on a recurring basis as of June 30, 2018, for each fair value hierarchy level:

June 30, 2018	Derivative Liabilities		Total
Level I	$	—	$	—
Level II	$	—	$	—
Level III	$	659,895	$	659,895

Income Taxes

Income Taxes

Foreign Currency Translation

Foreign Currency Translation

June 30,

2018

December 31,

2017

Balance sheet date

0.1275

0.128

Average rate for unaudited condensed statements of operations and comprehensive loss

0.1276

0.1283

Earnings (Loss) Per Share

Earnings (Loss) Per Share

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 29 R18.htm IDEA: XBRL DOCUMENT

ORGANIZATION (Tables)

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Purchase price allocation of acquisition

	Purchase Price Allocation
Fair value of consideration issued	$	250,000
Liabilities assumed		532,289
Total purchase consideration	$	782,289
Assets acquired	$	543,138
Intellectual Property/Technology		239,151
	$	782,289

XML 30 R19.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Property and equipment

	June 30, 2018			December 31, 2017
Office equipment	$	6,885		$	1,944
Less: Accumulated Depreciation		(1,056	)		(621	)
Property and Equipment, Net	$	5,829		$	1,323

Financial instruments that are measured at fair value on a recurring basis

June 30, 2018	Derivative Liabilities		Total
Level I	$	—	$	—
Level II	$	—	$	—
Level III	$	659,895	$	659,895

Relevant exchange rates used

June 30,

2018

December 31,

2017

Balance sheet date

0.1275

0.128

Average rate for unaudited condensed statements of operations and comprehensive loss

0.1276

0.1283

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Patents

Patents and trademarks	$	138,934
License rights		500,000
Accumulated amortization		(12,500	)
Net carrying amount	$	626,434

XML 32 R21.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Tables)

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

Summary of convertible note balance

	June 30, 2018			December 31, 2017
Principal balance	$	615,375		$	735,500
Unamortized discount		(402,357	)		-0-
Ending balance, net		213,018		$	735,500

XML 33 R22.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Tables)

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Summary of activity related to derivative liabilities

Beginning balance	$	-0-
Issued during period		1,450,030
Converted		(534,666	)
Change in fair value recognized in operations		(255,469	)
Ending balance	$	659,895

XML 34 R23.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

Note payables outstanding

	June 30, 2018
Note payable, interest at 8%, matures September 6, 2018	$	370,000
Note payable, includes $10,000 original issue discount, matures October 30, 2018		60,000
Note payable, interest		230,000
Other, due on demand		2,805
Total notes payable	$	662,805

XML 35 R24.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Tables)

6 Months Ended

Jun. 30, 2018

Expenses to officers

	Three months ended		Six months ended
	June 30, 2018		June 30, 2018
CEO, parent	$	30,000	$	60,000
CEO, subsidiary		30,000		60,000
COO		30,000		60,000
CFO		30,000		60,000
Total	$	120,000	$	240,000

Amounts owed to officers, included in accounts payable and accrued expenses, related party

	June 30, 2018		December 31, 2017
CEO, parent	$	80,989	$	46,631
CEO, subsidiary		63,899		-0-
COO		208,905		158,381
CFO		50,586		15,000
Total	$	404,379	$	220,012

XML 36 R25.htm IDEA: XBRL DOCUMENT

ORGANIZATION - Purchase price allocation of acquisition (Details)	6 Months Ended
	Jun. 30, 2018 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fair value of consideration issued	$ 250,000
Liabilities assumed	532,289
Total purchase consideration	782,289
Assets acquired	543,138
Intellectual Property/Technology	239,151
Total	$ 782,289

XML 37 R26.htm IDEA: XBRL DOCUMENT

ORGANIZATION (Details Narrative) - USD ($)	Apr. 13, 2018	Feb. 16, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Repurchase of common stock, shares	2,000,000
Repurchase of common stock, purchase price	$ 350,000
Spinus membership interest acquired		100.00%
Spinus acquisition, Company shares issued		5,000,000
Spinus acquisition, obligation to a third party assumed		$ 250,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Property and equipment (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Office equipment	$ 6,885	$ 1,944
Less: Accumulated Depreciation	(1,056)	(621)
Property and Equipment, Net	$ 5,829	$ 1,323

XML 39 R28.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Financial instruments that are measured at fair value on a recurring basis (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Derivative liabilities	$ 659,895
Level I
Derivative liabilities
Level II
Derivative liabilities
Level III
Derivative liabilities	$ 659,895

XML 40 R29.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Relevant exchange rates used (Details)	Jun. 30, 2018	Dec. 31, 2017
Balance sheet date
Exchange rate used, Hong Kong dollar per one U.S. dollar	.1275	.128
Average rate for unaudited condensed statements of operations and comprehensive loss
Exchange rate used, Hong Kong dollar per one U.S. dollar	.1276	.1283

XML 41 R30.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Accounting Policies [Abstract]
Depreciation expense	$ 273	$ 162	$ 435	$ 297
Advertising and marketing expenses			35,355	954
Research and development expenses		$ 41,856	$ 10,565	$ 84,237

XML 42 R31.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS - Patents (Details)	Jun. 30, 2018 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Patents and trademarks	$ 138,934
License rights	500,000
Accumulated amortization	(12,500)
Net carrying amount	$ 626,434

XML 43 R32.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
INTANGIBLE ASSETS (Details Narrative) - USD ($)	Jun. 30, 2018	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 2,206	$ 4,412

XML 44 R33.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE - Summary of convertible note balance (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Principal balance	$ 615,375	$ 735,500
Unamortized discount	(402,357)
Ending balance, net	$ 213,018	$ 735,500

XML 45 R34.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
2017 Notes
Proceeds received		$ 710,000
March 2018 Note
Convertible promissory notes, amount		50,000
Proceeds received		$ 50,000
Notes
Initial debt discount	$ 620,075
Interest expense	14,000
Initial derivative liability	634,075
Amortization of debt discounts charged to interest expense	398,886
Conversion of convertible debt, principal converted	570,500
Conversion of convertible debt, accrued interest converted	$ 19,857
Conversion of convertible debt, shares issued	1,180,768
Outstanding principal balance of note	$ 215,000
Carrying value of note	196,750
Unamortized discounts on note	18,250
Note Issued Pursuant to Securities Purchase Agreement
Convertible promissory notes, amount	442,175
Proceeds received	350,000
Original issue discount	57,675
Principal payments made on note	41,800
Initial debt discount	407,675
Interest expense	408,280
Initial derivative liability	815,955
Amortization of debt discounts charged to interest expense	106,243
Outstanding principal balance of note	400,375
Carrying value of note	16,268
Unamortized discounts on note	$ 384,107

XML 46 R35.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES - Summary of activity related to derivative liabilities (Details)	6 Months Ended
	Jun. 30, 2018 USD ($)
Notes to Financial Statements
Beginning balance
Issued during period	1,450,030
Converted	(534,666)
Change in fair value recognized in operations	(255,469)
Ending balance	$ 659,895

XML 47 R36.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Details Narrative)			6 Months Ended
DERIVATIVE LIABILITIES (Details Narrative)	Jun. 30, 2018	Apr. 13, 2018	Jun. 30, 2018
Notes to Financial Statements
Risk-free interest rate, minimum	2.06%	1.06%	1.89%
Risk-free interest rate, maximum	2.24%	1.28%	2.29%
Volatility, minimum	121.00%	140.00%	120.00%
Volatility, maximum	164.00%	260.00%	331.00%

XML 48 R37.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE - Note payables outstanding (Details)	Jun. 30, 2018 USD ($)
Debt Disclosure [Abstract]
Note payable, interest at 8%, matures September 6, 2018	$ 370,000
Note payable, includes $10,000 original issue discount, matures October 30, 2018	60,000
Note payable, interest	230,000
Other, due on demand	2,805
Total notes payable	$ 662,805

XML 49 R38.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS - Expenses to officers (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018
Expenses to officers	$ 120,000	$ 240,000
CEO, parent
Expenses to officers	30,000	60,000
CEO, subsidiary
Expenses to officers	30,000	60,000
COO
Expenses to officers	30,000	60,000
CFO
Expenses to officers	$ 30,000	$ 60,000

XML 50 R39.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS - Amounts owed to officers, included in accounts payable and accrued expenses, related party (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Due to related party	$ 404,379	$ 220,012
CEO, parent
Due to related party	80,989	46,631
CEO, subsidiary
Due to related party	63,899
COO
Due to related party	208,905	158,381
CFO
Due to related party	$ 50,586	$ 15,000

XML 51 R40.htm IDEA: XBRL DOCUMENT

LICENSE FEE PAYABLE (Details Narrative)	Feb. 16, 2018 USD ($)
Notes to Financial Statements
Spinus acquisition, obligation to a third party assumed	$ 250,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Narrative)	6 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative)	Jun. 30, 2018 USD ($) $ / shares shares
Equity [Abstract]
Common stock sold, shares \| shares	500,000
Common stock sold, price per share \| $ / shares	$ .50
Common stock sold, proceeds received \| $	$ 250,000
Conversion of convertible debt, aggregate principal and accrued interest \| $	$ 590,357
Conversion of convertible debt, shares issued \| shares	1,180,768
Conversion of convertible debt, conversion price \| $ / shares	$ .50

XML 53 R42.htm IDEA: XBRL DOCUMENT

GOING CONCERN AND MANAGEMENT'S PLANS (Details Narrative) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stockholders' deficit	$ (1,381,076)	$ (1,255,462)
Working capital deficit	$ (2,013,339)

XML 54 R43.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative)	Jul. 23, 2018 USD ($)
Subsequent Events [Abstract]
Equity Transfer Agreement, equity interest paid to sellers	$ 147,815
Equity Transfer Agreement, inventory value	$ 602,009

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 56 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 48 194 1 false 15 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://OZSC/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheet (Unaudited) Sheet http://OZSC/role/BalanceSheet Condensed Consolidated Balance Sheet (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) Sheet http://OZSC/role/BalanceSheetParenthetical Condensed Consolidated Balance Sheet (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statement of Comprehensive Loss (Unaudited) Sheet http://OZSC/role/StatementOfComprehensiveLoss Condensed Consolidated Statement of Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) Sheet http://OZSC/role/CondensedConsolidatedStatementOfCashFlows CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - ORGANIZATION Sheet http://OZSC/role/Organization ORGANIZATION Notes 6 false false R7.htm 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Sheet http://OZSC/role/SummaryOfSignificantAccountingPronouncements SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Notes 7 false false R8.htm 00000008 - Disclosure - INTANGIBLE ASSETS Sheet http://OZSC/role/IntangibleAssets INTANGIBLE ASSETS Notes 8 false false R9.htm 00000009 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://OZSC/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 9 false false R10.htm 00000010 - Disclosure - DERIVATIVE LIABILITIES Sheet http://OZSC/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 10 false false R11.htm 00000011 - Disclosure - NOTES PAYABLE Notes http://OZSC/role/NotesPayable NOTES PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://OZSC/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 12 false false R13.htm 00000013 - Disclosure - LICENSE FEE PAYABLE Sheet http://OZSC/role/LicenseFeePayable LICENSE FEE PAYABLE Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://OZSC/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - GOING CONCERN AND MANAGEMENT'S PLANS Sheet http://OZSC/role/GoingConcernAndManagementsPlans GOING CONCERN AND MANAGEMENT'S PLANS Notes 15 false false R16.htm 00000016 - Disclosure - SUBSEQUENT EVENTS Sheet http://OZSC/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) Sheet http://OZSC/role/SummaryOfSignificantAccountingPronouncementsPolicies SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - ORGANIZATION (Tables) Sheet http://OZSC/role/OrganizationTables ORGANIZATION (Tables) Tables http://OZSC/role/Organization 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) Sheet http://OZSC/role/SummaryOfSignificantAccountingPronouncementsTables SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) Tables http://OZSC/role/SummaryOfSignificantAccountingPronouncements 19 false false R20.htm 00000020 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://OZSC/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://OZSC/role/IntangibleAssets 20 false false R21.htm 00000021 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) Notes http://OZSC/role/ConvertibleNotesPayableTables CONVERTIBLE NOTES PAYABLE (Tables) Tables http://OZSC/role/ConvertibleNotesPayable 21 false false R22.htm 00000022 - Disclosure - DERIVATIVE LIABILITIES (Tables) Sheet http://OZSC/role/DerivativeLiabilitiesTables DERIVATIVE LIABILITIES (Tables) Tables http://OZSC/role/DerivativeLiabilities 22 false false R23.htm 00000023 - Disclosure - NOTES PAYABLE (Tables) Notes http://OZSC/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://OZSC/role/NotesPayable 23 false false R24.htm 00000024 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://OZSC/role/RelatedPartyTransactionsTables RELATED PARTY TRANSACTIONS (Tables) Tables http://OZSC/role/RelatedPartyTransactions 24 false false R25.htm 00000025 - Disclosure - ORGANIZATION - Purchase price allocation of acquisition (Details) Sheet http://OZSC/role/Organization-PurchasePriceAllocationOfAcquisitionDetails ORGANIZATION - Purchase price allocation of acquisition (Details) Details 25 false false R26.htm 00000026 - Disclosure - ORGANIZATION (Details Narrative) Sheet http://OZSC/role/OrganizationDetailsNarrative ORGANIZATION (Details Narrative) Details http://OZSC/role/OrganizationTables 26 false false R27.htm 00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Property and equipment (Details) Sheet http://OZSC/role/SummaryOfSignificantAccountingPronouncements-PropertyAndEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Property and equipment (Details) Details 27 false false R28.htm 00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Financial instruments that are measured at fair value on a recurring basis (Details) Sheet http://OZSC/role/SummaryOfSignificantAccountingPronouncements-FinancialInstrumentsThatAreMeasuredAtFairValueOnRecurringBasisDetails SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Financial instruments that are measured at fair value on a recurring basis (Details) Details 28 false false R29.htm 00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Relevant exchange rates used (Details) Sheet http://OZSC/role/SummaryOfSignificantAccountingPronouncements-RelevantExchangeRatesUsedDetails SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS - Relevant exchange rates used (Details) Details 29 false false R30.htm 00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) Sheet http://OZSC/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) Details http://OZSC/role/SummaryOfSignificantAccountingPronouncementsTables 30 false false R31.htm 00000031 - Disclosure - INTANGIBLE ASSETS - Patents (Details) Sheet http://OZSC/role/IntangibleAssets-PatentsDetails INTANGIBLE ASSETS - Patents (Details) Details 31 false false R32.htm 00000032 - Disclosure - INTANGIBLE ASSETS (Details Narrative) Sheet http://OZSC/role/IntangibleAssetsDetailsNarrative INTANGIBLE ASSETS (Details Narrative) Details http://OZSC/role/IntangibleAssetsTables 32 false false R33.htm 00000033 - Disclosure - CONVERTIBLE NOTES PAYABLE - Summary of convertible note balance (Details) Notes http://OZSC/role/ConvertibleNotesPayable-SummaryOfConvertibleNoteBalanceDetails CONVERTIBLE NOTES PAYABLE - Summary of convertible note balance (Details) Details 33 false false R34.htm 00000034 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://OZSC/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://OZSC/role/ConvertibleNotesPayableTables 34 false false R35.htm 00000035 - Disclosure - DERIVATIVE LIABILITIES - Summary of activity related to derivative liabilities (Details) Sheet http://OZSC/role/DerivativeLiabilities-SummaryOfActivityRelatedToDerivativeLiabilitiesDetails DERIVATIVE LIABILITIES - Summary of activity related to derivative liabilities (Details) Details 35 false false R36.htm 00000036 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) Sheet http://OZSC/role/DerivativeLiabilitiesDetailsNarrative DERIVATIVE LIABILITIES (Details Narrative) Details http://OZSC/role/DerivativeLiabilitiesTables 36 false false R37.htm 00000037 - Disclosure - NOTES PAYABLE - Note payables outstanding (Details) Notes http://OZSC/role/NotesPayable-NotePayablesOutstandingDetails NOTES PAYABLE - Note payables outstanding (Details) Details 37 false false R38.htm 00000038 - Disclosure - RELATED PARTY TRANSACTIONS - Expenses to officers (Details) Sheet http://OZSC/role/RelatedPartyTransactions-ExpensesToOfficersDetails RELATED PARTY TRANSACTIONS - Expenses to officers (Details) Details 38 false false R39.htm 00000039 - Disclosure - RELATED PARTY TRANSACTIONS - Amounts owed to officers, included in accounts payable and accrued expenses, related party (Details) Sheet http://OZSC/role/RelatedPartyTransactions-AmountsOwedToOfficersIncludedInAccountsPayableAndAccruedExpensesRelatedPartyDetails RELATED PARTY TRANSACTIONS - Amounts owed to officers, included in accounts payable and accrued expenses, related party (Details) Details 39 false false R40.htm 00000040 - Disclosure - LICENSE FEE PAYABLE (Details Narrative) Sheet http://OZSC/role/LicenseFeePayableDetailsNarrative LICENSE FEE PAYABLE (Details Narrative) Details http://OZSC/role/LicenseFeePayable 40 false false R41.htm 00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://OZSC/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://OZSC/role/StockholdersEquity 41 false false R42.htm 00000042 - Disclosure - GOING CONCERN AND MANAGEMENT'S PLANS (Details Narrative) Sheet http://OZSC/role/GoingConcernAndManagementsPlansDetailsNarrative GOING CONCERN AND MANAGEMENT'S PLANS (Details Narrative) Details http://OZSC/role/GoingConcernAndManagementsPlans 42 false false R43.htm 00000043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://OZSC/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://OZSC/role/SubsequentEvents 43 false false All Reports Book All Reports ozsc-20180630.xml ozsc-20180630.xsd ozsc-20180630_cal.xml ozsc-20180630_def.xml ozsc-20180630_lab.xml ozsc-20180630_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/currency/2017-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 61 0001554795-18-000257-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001554795-18-000257-xbrl.zip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